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The main objective of this research is to develop and identify a novel class of 
compounds that can be used to treat metastatic breast cancer. To our knowledge no study 
concerning the anti-breast cancer activity of chalcone and chalcone-like derivatives 
containing the adamantyl moiety has been reported in the current available literature. 
This thesis contains the first reported study specifically focused on the activity of 
chalcone and chalcone-like derivatives containing the adamantyl moiety against breast 
cancers. 
Many chalcone, flavanone and isoflavanone derivatives are known to exhibit 
antiproliferative effects against breast cancer cells and display binding affinities for the 
ER. Adamantane shows abroad spectrum of biological activity and its addition to organic 
compounds can enhance their biological activity. A total of twenty four adamantyl 
chalcone and chalcone-like compounds were synthesized and characterized. These 
compounds were conveniently divided into four categories: 1) Senes I. Chalcone-like 
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compounds with the aromatic A ring replaced by the adamantane moiety; 2) Series II. 
Chalcone-like compounds with modification in the A ring and B region; 3) Series III. 
Chalcone-like compounds with the aromatic C ring replaced by heterocyclic group; and 
4) Series IV. Chalcone with the adamantane moiety substituted on the aromatic A ring. 
The Aldol condensation method was used as a convenient way to modify the chalcone 
structure. Iron filings were used as a catalyst in a new synthetic method for the 
adamantylation of benzene derivatives. This new method provided for easy separation 
and afforded high percent yield of product. These compounds were characterized by 
melting point, elemental analysis, GC-MS, FT-IR, FT-NMR, and X-ray. Selected 
compounds from each series were then tested for biological activity in breast cancer 
derived cell lines MCF-7 (ER-positive), MDA-MB435 (ER-negative) and a control breast 
cancer cell line (MCF-10). One compound from series I and five compounds from series 
III were effective in prohibiting cell growth in the selected cancer cell lines but not in the 
control cell line. The lethal concentration at 50% (LC50) values in MCF-7 range from 5 
X 10'3 M to 5 X 10"5 M and in MDA-MB435, the LC50 values range from 1 X I0"3 to 5 X 
10"6. The control cell line showed no significant decrease in cell viability in the presence 
of these compounds. 
The ability of the parent compound 47a to reduce the sensitivity of the cell lines 
towards epidermal growth factor (EGF) and transforming growth factor-a (TGF-a) were 
tested. Compound 47a in MCF-7 cell line reversed stimulatory effect of EGF but the 
stimulatory effect of TGF-a was reversed in MDA-MB435 cell line. 
Some of the newly synthesized compounds showed greater activity than currently 
used drugs such as tamoxifen, genestein and doxyrubicin. 
2 
THE DESIGN, SYNTHESIS, CHARACTERIZATION AND BIOLOGICAL 
SCREENING EVALUATION OF 1-ADAMANTYL CHALCONES AS 
POTENTIAL BREAST CANCER AGENTS 
A DISSERTATION 
SUBMITTED TO THE FACULTY OF CLARK ATLANTA UNIVERSITY 
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR 
THE DEGREE OF DOCTOR OF PHILOSOPHY 
BY 
TAWFEQ ABDUL-RAHEEM KAIMARI 




TAWFEQ A. KAIMARI 
All Rights Reserved 
ACKNOWLEDGEMENTS 
First and foremost, I would like to thank ALLAH (Subhanahu Wataala) for 
guiding me toward my goals. I would like to thank my father, Abdul-Raheem Kaimari, 
who has taught me that through curiosity, careful reasoning, honesty, persistence, and 
faith all things in life are possible. My mother, Mukarram Maswadeh, who has been the 
inspirational force behind all of my accomplishment. My wife, Reem Kaimari, whose 
relationship with me has made the good times great and the rough times tolerable. She is 
a super woman who supported me emotionally during my doctoral work, “you are the 
wind beneath my wings.” 
I would also like to thank my research advisor, Professor Gloria Anderson. She 
allowed considerable latitude to conduct this research project, generously gave morai and 
intellectual support, as well as guidance and prudent advice. I would also like to express 
my appreciation to the members of my committee: Drs. Reynold Verret and Eric Mintz 
for believing in me and allowing me to complete this work. Dr. Nasser Zawia for the 
deep discussions about the meaning of pharmacology in relation to my research. Drs. 
James Bu and Paul McGadey for their intellectual discussion. Dr. Evans is posthumously 
acknowledged for his support and contribution to my research, he will be missed. Finally 
I would like to thank several colleagues who contributed greatly to my success. Drs. 
Peter Roessle and Karen Fulford for their tremendous help and support through this work. 
Dr. Gabriel Garcia for his great friendship and Dr. Duane Johnson and his wife Katana 
Johnson for there helped in setting up the biological experiments. Funding of this work 
through the chemistry department at Morris Brown College is appreciated. 
11 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS 1 
LIST OF FIGURES vii 
LIST OF TABLES viii 
CHAPTER ONE 
INTRODUCTION  1 
BREAST CANCER  1 
Occurrence 1 
Cancer Therapy 3 
The Involvment of the Estrogen Receptor in Breast Cancer 4 
Common Chemotherapeutic Agents  12 
Antiestrogens  12 
Other Chemotheraputic Agents 17 
Need for New Drugs   20 
CHALCONES 21 
General Biological Activity 22 
Anti-tumor Activity 23 
Anti Breast Cancer Activity 25 
1-SUBSTITUTED ADAMANTANE DERIVATIVES 27 
General Biological Activity 27 
Anti-tumor Activity 28 
Anti-Breast Cancer Activity 30 
CHAPTER TWO 
RESULTS AND DISCUSSION 32 
SYNTHESIS AND CHARACTERIZATION 32 
Series I. Synthesis of Chalcone-Likes Compounds 43 with Aromatic A Ring Replaced by 
Adamantane Moiety 33 
Series II. Chalcone-Like Compounds 45 with Modification in A and B Regions 38 
iii 
Table of Contents Continued 
Series III. Chalcone-Like Compounds 47 with Aromatic C Ring Substituted By Heterocycle 
group 39 
Series IV. Synthesis of Chalcones 58 with Adamantane Moiety Substituted on Aromatic 
Ring A 39 
EVALUATION OF COMPOUNDS FOR BREAST CANCER ACTIVITY 47 
Mechanisms of Antiestrogen Action 47 
Interactions with Estrogen Response Elements 49 
Antiestrogens and the Cell Cycle 50 
General Screening Results 53 
Antiestrogens and Growth Factors 65 
Transforming Growth Factor a 65 
Transforming Growth Factor P 67 
EGF & TGF-a stimulated Growth of MCF-7 and MDA-MB 435 72 
EGF-Serum and non-Serum stimulated growth of MCF-7 cells 72 
TGF-a Serum and non-Serum Stimulated Growth of MCF-7 Cells 74 




Synthesis of Series I. Chalcone-Like Compounds 43 with Aromatic A Ring Replaced by 
Adamantane Moiety 86 
Synthesis of Series II. Chalcone-Like Compounds 45 with Modification in A and B Regions 87 
Synthesis of Series III. Chalcone-Like Compounds £7 with Modification in A and C Regions 88 
Synthesis of Series IV. Adamantane Moiety Substituted on Aromatic A Ring 52 90 
Cell Culture Methods 92 
In Vitro Biological Screening 93 
Cell Proliferation Studies 94 
Growth Factor Protocol 95 
APPENDIX A CRYSTALLOGRAPHIC DATA AND ANALYSIS FOR COMPOUND 43g 97 
IV 
APPENDIX B CRYSTALLOGRAPHIC DATA AND ANALYSIS FOR COMPOUND 43h 102 
APPENDIX C CRYSTALLOGRAPHIC DATA AND ANALYSIS FOR COMPOUND 54c 107 
APPENDIX C NMR DATA FOR SERIES I COMPOUNDS 115 
APPENDIX D NMR DATA FOR SERIES II COMPOUNDS 117 
APPENDIX E NMR DATA FOR SERIES III COMPOUNDS 118 
APPENDIX F NMR DATA FOR SERIES IV COMPOUNDS 119 
APPENDIX G TISSUE CULTURE PROCEDURES 120 
PREPARATION OF RPMI 1640 WITH 10% FBS MEDIA:  120 
FEEDING OF CELLS/CHANGING MEDIA OF CELLS:  120 
SPLITTING/TRYPSINIZING OF CELLS: 120 
COUNTING OF CELLS:  121 
ADDING CELLS TO THE 96 WELL PLATE:  121 
ADDITION OF DRUG TO THE PLATE: 122 
ADDITION OF ALAMAR BLUE: 122 
ANALYZING OF DATA:  122 
REFERENCES 123 
LIST OF FIGURES 
Figure Page 
1. The ER consists of six functional domains  6 
2. Estradiol (E2) action is transduced through the ER located in the 
nucleus  8 
3. Melting point determination on the Electrothermal 9200 melting point 
apparatus  35 
4. Crystal Structure of Compound 43h  37 
5. Crystal Structure of Compound 43g  37 
6. Comparison between free radical vs. ionic adamantylation  44 
7. Crystal structure of compound 54c  45 
8. The current molecular model of antiestrogen action  48 
9. Percent Cell Viability of Selected Compounds From Series I Tested 
On MCF-7 (ER+) Breast Cancer Cell Lines ,. 54 
10. Percent Cell Viability of Selected Compounds From Series I Tested 
On MD MBA-435 (ER-) Breast Cancer Cell Lines  54 
11. Percent Cell Viability of Selected Compounds From Senes II Tested 
On MCF-7 (ER+) Breast Cancer Cell Lines  55 
12. Comparison of the LC50 Values Produced in Human Breast Cancer 
Line MCF-7 cells treated with synthesized compounds (47a-e) and 
with known anti-cancer agents Tamoxifen, Genestein, and 
Doxorubicin  57 
13. Comparison of the LC50 Values Produced in Human Breast Cancer 
Line MDA-MB435 cells treated via treatment with synthesized 
compounds (47a-e) and with known anti-cancer agents Tamoxifen, 
Genestein, and Doxorubicin  58 
VI 
List Of Figures Continued 
14. Comparison of the dose-response % cell death induced in Human 
Breast Cancer Line MCF-7 cells treated via treatment with 
synthesized compounds (47a-e) and with known anti-cancer agents 
Tamoxifen, Genestein, and Doxorubicin  59 
15. Comparison of the dose-response % cell death induced in Human 
Breast Cancer Line MDA-MB435 cells treated via treatment with 
synthesized compounds (47a-e) and with known anti-cancer agents 
Tamoxifen, Genestein, and Doxorubicin  59 
16. Dose Response % Cell Viability(control) vs Molar concentration of 
47a-e, Genestein, and Tamoxifen against MCF-10 cells  61 
17. Percent Cell Viability of 58 Compounds From Series IV Tested On 
MCF-7 (ER+) Breast Cancer Cell Lines  61 
18. Effectiveness of 47a for reducing EGF(lng/ml)+Serum-Stimulated 
Growth of MCF-7 Cells  73 
19. Effectiveness of £7a for reducing EGF(lng/ml)+Non Serum- 
Stimulated Growth of MCF-7 Cells  73 
20. Effectiveness of 47a for reducing TGF(lng/ml)+Serum-Stimulated 
Growth of MCF-7 Cells  74 
21. Effectiveness of 47a for reducing TGF(lng/ml)+Non Serum- 
Stimulated Growth of MCF-7 Cells  75 
22. Effectiveness of 47a for reducing EGF(lng/ml)+Serum-Stimulated 
Growth of MDA-MB435  76 
23. Effectiveness of 47a for reducing EGF(lng/ml)+Non Serum- 
Stimulated Growth of MDA-MB435 Cells  77 
24. Effectiveness of 47a for reducing TGF(lng/ml)+Serum-Stimulated 
Growth of MDA-MB435  77 
25. Effectiveness of 47a for reducing TGF(lng/ml)+Non Serum- 
Stimulated Growth of MDA-MB435  78 
26. Percent Cell Viability(control) of 47 a-e Tamoxifen, Doxorubicin, and 
Genestein Against MCF-7 cells at ImM  79 
vii 
LIST OF TABLES 
Table Page 
1. Chalcone-Like Compounds 43 Synthesized with Aromatic A Ring 
Replaced by the Adamantane Moiety  34 
2. Proton NMR Chemical Shifts and Coupling Constants for Ha and Hb 36 
3. Chalcone-Like Compounds 45 Synthesized with Modification in the 
A and B Regions  38 
4. Chalcone-Like Compounds 47 Synthesized with Aromatic C Ring 
Substituted by Heterocyclic Ring  40 
5. Some 1-Aryladamantanes 54 Synthesized By this Method  42 
6. LC50 Data for Administered Drug  80 
7. Series I. Elemental Analysis Data for Chalcone-Like Compounds 43 
Synthesized with Aromatic A Ring Replaced by the Adamantane 
Moiety  86 
8. Series I. GC-MS Data for Chalcone-Like Compounds 43 
Synthesized with Aromatic A Ring Replaced by the Adamantane 
Moiety  87 
9. Series II. Elemental Analysis Data For Chalcone-Like Compounds 45 
Synthesized with Modifications in A and B Regions  88 
10. Series II. GC-MS Data For Chalcone-Like Compounds 45 
Synthesized with Modifications in A and B Regions  88 
11. Series III. Elemental Analysis Data for Chalcone-Like Compounds £7 
with Aromatic C Ring Substituted by Heterocycle Ring  89 
12. Series III. GC-MS Data for Chalcone-Like Compounds £7 with 
Aromatic C Ring Substituted by Heterocycle Ring  89 
viii 
List of Tables Continued 
13. Series IV. Elemental Analysis Data for l-Adamantyl-4-substituted 
Benzenes 54  90 
14. Series IV. GC-MS Data for l-Adamantyl-4-substituted Benzenes 
5  90 
15. Crystal Data and Experimental Details for 43g  97 
16. Fractional Atomic Coordinates and Equivalent Isotropic Thermal 
Parameters (Â2) for 43g  98 
17. Interatomic Distances d (A) in the Structure of 43g  99 
18. Torrsion Angles in the Structure 43g (deg)  100 
19. Bond Angles co (degrees) in the Structure of 43g  101 
20. Crystal Data and Experimental Details for 43h  102 
21. Fractional Atomic Coordinates and Equivalent Isotropic Thermal 
Parameters (À2) for 43h  103 
22. Interatomic Distances d (Â) in the Structure of 43h  104 
23. Bond Angles on (degrees) in the Structure of 43h  105 
24. Torrsion Angles in the Structure 43h (deg)  106 
25. Crystal Data and Experimental Details for Compound 54c  108 
26. Fractional Atomic Coordinates and Equivalentlsotropic Thermal 
Parameters (Â2) for 54C  109 
27. Interatomic Distances d (À) in the Structure of 54C  Ill 
28. Bond Angles co (degrees) in the Structure of 54C  112 
29. Torrsion Angles in the Structure 54C (deg)  114 
30. Series I. 1H and l3C NMR Data for Chalcone-Like Compounds 43 
Synthesized with Aromatic A Ring Replaced by the Adamantane 
Moiety  115 
31. Series II. 'H and l3C NMR Data For Chalcone-Like Compounds 45 
Synthesized with Modifications in A and B Regions  117 
IX 
List of Tables Continued 
32. Series III. 'H and l3C NMR Data for Chalcone-Like Compounds £7 
with Aromatic C Ring Substituted by Heterocycle Ring  118 
33. Series IV. 'H and l3C NMR Data for Synthesized Chalcones with 





Breast cancer is the second leading cause of cancer deaths among women in the 
United States, second only to lung cancer; it is the leading cause of cancer deaths among 
women aged 40 to 55 years. Breast cancer is the most common malignant neoplasm in 
women worldwide. The American Cancer Society estimated that in 1998, about 178,700 
new cases of invasive breast cancer would be diagnosed among women in the United 
States. In addition, an estimated 1600 cases would be diagnosed among men. Statistics 
indicate that in 1998, there were about 43,900 deaths from breast cancer in the United 
States.1 It is expected that by the year 2000 there will be an estimated one million new 
diagnosed cases of breast cancer and an excess of 400.000 deaths per year world wide. 
Breast cancer accounts for almost one-third of all new cancer diagnoses in women and 
almost 20% of cancer-related female deaths.2 
The development of breast cancer has long been speculated to be linked to 
estrogen stimulation derived from the ovaries. In 1900, Stanley Boyd demonstrated that 
one-third of the premenopausal women diagnosed with breast cancer benefited from 
ovarectomies (removal of ovaries). It is now known that the reduction of the estrogen 
levels that accompany ovarectomy is responsible for this effect, and that any form of 
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endocrine therapy that decreases estrogen levels will benefit approximately one-third of 
breast cancer patients with pre- or post-menopausal breast cancer.3 
One of the risk factors associated with increased chance of breast cancer 
development is genetic pre-disposition. A woman with a first-degree relative with breast 
cancer is about two to three times more likely to develop breast cancer than a woman 
with a negative family history.4 This average figure is inappropriate for individual 
counseling since this group includes at least three subgroups with very different risks of 
breast cancer. For a second group of families, the risk is intermediate (about 30 %). In a 
final group, the risk is identical to that of the normal population, namely about 12% over 
a lifetime.5 
Most of the patients with hereditary breast cancer are thought to have a mutant 
BRACA1 or BRACA2 gene. In one study of 33 families with evidence of linkage to 
BRACA1 or BRACA2 gene, the lifetime risk of breast cancer was 87% by age 70.6 
The incident and mortality rates for breast cancer are highly variable around the 
world. Studies of migrating populations point to the importance of environmental factors 
in etiology of breast cancer, especially dietary factors. Women living in Japan have a 
low incidence of breast cancer in contrast to Japanese immigrants to the United States, 
particularly the female offspring of such immigrants. In humans, the rate of breast cancer 
increases with obesity.7 
Another etiological factor associated with breast cancer can be exposure to 
environmental chemicals and carcinogens, which induce breast neoplasms by generating 
DNA mutations at a faster rate than the DNA repair system can correct.8 
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Cancer Therapy 
Cancers can be classified according to their different locations in the body: local, 
regional, or metastatic. Locally growing tumors are restricted to one area with no sign of 
cancer in nearby lymph nodes or other tissue. Regional cancer involves growth of the 
tumor in the lymph nodes or tissues near one area, but there is no evidence of the cancer 
at distant places on the body. Metastatic growth involves the cancer being spread to 
organs or other tissues far from the original site. Various cancer treatments are designed 
to destroy the cancer. The methods of treatment depend on the type of cancer, its size, 
and location. Current treatment for cancers includes: 1) surgery, 2) radiation, 3) 
chemotherapy, 4) hormonal therapy (when reproductive organs are involved), and 5) 
molecular antibody therapy.9 
Surgery and radiation may be used to treat localized cancers. After surgery, 
radiation may be used to stop the growth of any cancerous cells that remain in certain 
parts of the body.10 Chemotherapy involves the use of drugs to slow the growth of 
cancerous cells. These drugs may be used alone or in combination with radiation, 
surgery, or hormonal therapy. Because anticancer drugs can reach affected sites of 
rapidly growing cells that are far away from the original site, chemotherapy is the 
primary treatment for many kinds of cancers that have spread beyond single sites or 
regions. Due to the fact that chemotherapeutic agents mostly affect rapidly growing cells 
in the body, the proliferations of normal cells, as well as cancer cells are affected. 
Certain cancers are sensitive to changes in hormone levels. Adding, removing, or 
limiting the activity of certain hormones can impede the growth or activity of certain 
types of cancer cells." 
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Breast cancer is divided in four different stages. Stage 0: Ductal carcinoma in situ 
(DCIS) is the earliest form of breast cancer. In DCIS, cancer cells are located within a 
duct and have not escaped into the surrounding fatty breast tissue. Stage I: The tumor 
does not appear to have spread beyond the breast. Stage II: The tumor has spread to the 
lymph nodes under the arm on the same side as the breast cancer. At this stage, the 
lymph nodes are not stuck to one another or to the surrounding tissues. Stage III: The 
tumor has spread to the lymph nodes that are fixed (attached) to one another or to the 
surrounding tissue and has spread to the skin or the chest wall. Stage IV: The cancer, 
regardless of its size, has metastasized to distant organs such as bones, lungs or to lymph 
nodes not near the breast. Multiple chemotherapeutic agents and regimens exist with 
documented antitumor activity against breast cancer; however, less than one in five 
patients with stage IV breast cancer are alive 5 years from the first detection of distant 
métastasés.12 Although improved response proportions have been observed, overall 
survival for patients with metastatic breast cancer has not been significantly improved by 
the progress of the past three decades. 13 Furthermore, despite the proven magnitude of 
benefit of adjuvant systemic therapy (when it is given to patients with no detectable 
cancer after surgery) in reducing the risk of recurrence, a significant fraction of patients 
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with early stage breast cancer still will relapse and ultimately die of metastatic disease. 
Clearly new active agents and strategies are needed to improve upon this situation. 
The Involvment of the Estrogen Receptor in Breast Cancer 
The first evidence for a connection between estrogen and breast cancer growth 
was presented in 1896 when Beatson, a British physician, discovered that by removing 
the ovaries of premenopausal women, he could cause a regression of advanced breast 
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tumors. Shortly thereafter, Stanley Boyd (1900) reported a study that established that 
one-third of all patients with breast cancer who had an oophorectomy (surgery to remove 
the ovaries) would see a regression of their disease. However, the mechanism by which 
this occurred in these patients and who would respond were not to be discovered until 60 
years later. The Estrogen Receptor (ER) first was described in the uterus of rats,14 and 
extensive early literature on the basic biochemistry of the ER quickly developed.15,16,17 
Jensen and collagues translated the basic science into clinical utility by proposing a 
predictive test, the ER assay, to determine which patients would respond to endocrine 
ablation, i.e., oophorectomy in premenopausal patients and adrenalectomy in 
postmenopausal patients.18 It was then established that patients with ER-rich tumors 
respond to endocrine therapy, whereas patients with ER-negative tumors are unlikely to 
respond.19 These pivotal observations provide an excellent example of basic research 
that translated to the treatment of human disease. 
Nuclear hormone receptors are a family of hormone-activated transcription 
factors that initiate or enhance the transcription of genes containing specific hormone 
response elements. The Human ER, which belongs to this family, was cloned and 
sequenced from MCF-7 human breast cancer cells.20'21 The ER protein consists of 595 
amino acids with a molecular weight of 66 kDa,20 and has been separated into six 






Ligand Binding Domain 
AF-2 
H2N A/B C D E F COOH 
180 263 302 A A ▲ 553 595 
351 400 540 
îî î 
■ 
Figure 1. The ER consists of six functional domains 
Two of these functional domains are highly conserved in the primary sequence of 
members of the nuclear hormone receptor superfamily (A/B in Figure 1). One of the 
domains (C in Figure 1), the DNA binding domain (DBD), contains two zinc fingers that 
mediate receptor binding to hormone response elements in the promoters of hormone- 
responsive genes. In the C-terminal region, the hormone-binding domain (HBD, E in 
Figure 1) contains two regions of sequence homology with other hormone receptors and 
bestows hormone specificity and selectivity.23'24,25 
The model for estrogen action via the ERa (henceforth referred to as ER) has 
evolved considerably during the past 40 years. The first realistic conceptual model was 
proposed by Mueller and colleagues to explain the initiation of metbolic events in the rat 
uterus by estrogen.27 Since then, several models have evolved that address the 
mechanism of how the ER functions in the nucleus and how it activates the transcription 
of estrogen-responsive genes in the presence of estrogens, an effect differentially blocked 
by antiestrogens.28 
The six structural domains of the ER are regions that have been defined based on 
the putative functions that are contained in each area. The ER contains two areas called 
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AFs: activation functions-1 (AF-1) is located in the amino-terminal region of the ER, and 
activation functions-2 (AF-2) is located in the carboxyl-terminal region in the ligand 
binding domain (LBD) of the ER; these are synergistic when the ER is activated by 
estrogen. AF-1 and AF-2 are autonomous in that they are located at the N- and C- 
termini, respectively. Activation function-1 (AF-1) is thought to be responsible for the 
promoter-specific transcriptional activation independent of the presence of ligand and 
AF-2 provides ligand-specific activation.29 
The C region contains the DBD and a dimerization domain. The DBD is the most 
highly conserved region in the nuclear hormone receptor superfamily. The DBD consists 
of two zinc fingers that fold into two helical domains upon the coordination of one zinc to 
four cysteines and a third helix that extends from the zinc fingers.30 These zinc fingers 
are essential components of the ER because when the ER lacks the DBD, it cannot bind 
DNA in vitro or in vivo. However, the C region alone is not sufficient to bind an 
Estrogen Response Element (ERE). The A/B region can be deleted without 
compromising the DNA binding ability but deletion of the basic amino acids (amino 
acids 256 to 270) located down-stream of the zinc fingers does impair the ability of the 
receptor to bind EREs.31 
There are many similarities in the zinc finger regions among different steroid 
hormone receptors, but there are precise differences that account for the specificity of 
each receptor. It is believed that the specificity of a certain receptor is afforded by the 
first of the two zinc fingers. These conclusions are based on mutagenesis (changes of 
Cys to Gly) in the region of the first finger. The results prove that the receptor binds to 
specific nucleic acid residues in the major groove of the DNA helix. The second zinc 
finger is responsible for stabilizing this interaction through ionic bonds with the 
phosphate groups in the DNA backbone.32 In addition to these mutational studies, 
domain-swapping experiments in which the ER DBD was exchanged with the DBD of 
the glucocorticoid receptor showed that the chimeric protein activates glucocorticoid 
responsive genes in the presence of estrogen.33 
Estrogen diffuses through the plasma membrane of cells where it binds to the 
ER.’4 For many years, it generally was thought that estrogen bound to the ER in the 
cytoplasm and translocated into the nucleus, but it is known now that the ER is a nuclear 
transcription factor that initially interacts with estrogen in the nucleus.'5 Once estrogen 
binds to the ER, a change in conformation and homodimerization occurs Figure 2. 
Figure 2. Estradiol (E2) action is transduced through the ER located in the nucleus. 
Although phosphorylation of steroid hormone receptors enables them to become 
transcriptionally active, until recently, the role of phosphorylation of the ER was still in 
question.2'^ Phosphorylation of the ER from MCF-7 and calf uterus is estrogen-dependent 
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and, in addition, increases the receptor’s affinity for specific DNA sequences.36 The 
basal level of ER phosphorylation increases three-to four-fold upon treatment with 
estrogen and antiestrogens.37 However, the key to elucidating the mechanism of estrogen 
action is the identification of the selective sites for phosphorylation. Several serines in 
the amino-terminal portion of the human ER may play a role in hormone-regulated 
phosphorylation. However, when phosphopeptide maps of wild-type and mutant ERs 
treated with estrogen or antiestrogens are compared, the results are similar indicating that 
differential phosphorylation between these receptors cannot account for any differences 
TO 
in function.' An alternate approach might be the identification of enzymes responsible 
for phosphorylation. There are several protein kinases thought to be involved in 
phosphorylation of the ER (ER kinase, protein kinase C. protein kinases A, and casein 
kinase II).39 Recently, a mitogen-activated protein kinase also was implicated in 
phosphorylation of the ER on Ser 118 resulting in the activation of ER AF-1.40 
Interestingly, another consequence of phosphorylation of the ER is the regulation of 
homodimerization through phosphorylation of tyrosine 537.41 
Although phosphorylation may play a part in receptor activation, exciting 
progress has been made in understanding how the receptor cooperates with other proteins 
to assemble a transcription unit for gene activation. The receptor can be viewed as a 
skeleton to assemble the unit as a prelude to DNA unwinding and the transcription of 
selected mRNAs. To achieve this, the receptor eventually must interact with other 
proteins as well as bind to one or several EREs. 
As stated above, the ER contains two areas called AFs: AF-1 is located in the 
amino-terminal region of the ER, and AF-2 is located in the carboxyl-terminal region in 
10 
the ligand binding domain (LBD) of the ER; these are synergistic when the ER is 
activated by estrogen. Katzenellenbogen and colleagues used mammalian cells to show 
that the AF-1 and AF-2 regions, when expressed as separate polypeptides, functionally 
interact in response to estrogen and antiestrogens.42 The authors found that this 
interaction could activate transcription in response to estrogen. In addition, when 
mutations were made in AF-1 or AF-2, the functional activity of these domains was 
inhibited, no transcriptional activity was seen. Additionally, when mutations were made 
in the LBD, estrogen binding was eliminated and no transcriptional activity could be 
detected. These experiments suggested that estrogen binding to the ER facilitates a 
conformational change that brings AF-1 and AF-2 in direct association with one another 
leading to synergy that results in transcriptional activation. These experiments provide a 
mechanistic explanation for the role of the two AFs in mediating hormone-regulated 
transcription. 
In addition to understanding the mechanism through which the ER becomes 
transcriptionally active, many of the amino acids important in the binding of ligand to the 
ER have been identified. Harlow and coworkers showed a covalent attachment between 
Cys530 and both estrogen agonist and an antagonist.43 This work also suggested that 
other cysteine residues present in the LBD might be important for ligand-mediated 
transcriptional activation. Further mutant ERs have been constructed with mutations at 
the other cysteine residues present in the LBD. Each of these mutants showed an affinity 
similar to that of the wild-type ER 44 When these mutants were tested in reporter assays, 
the mutants C530A and C530S showed unaltered binding to estrogens and antiestrogens, 
but the transactivation response to both estrogens and antiestrogens had changed. After 
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showing that the C530 is involved in discriminating between ligands, Pakdel and 
Katzenellenbogen examined the role of amino acids adjacent to the other cysteines in the 
LBD of the ER.45 The results showed that the amino-terminal domain of the LBD was 
important in differential transcriptional activation but not in binding affinity. When the 
carboxyl-terminal region of the LBD is mutated, this renders the protein transcriptionally 
inactive although it can still bind ligand, making this a very powerful dominant negative 
ER. Thus, there is a distinction between the hormone binding and the transactivation 
functions. 
Once the ER has bound estrogen and dimerized, it binds to EREs present in the 
promoter region of genes. These EREs are 13 base pair palindromic sequences located 
upstream from the transcriptional start site. The EREs function by enhancing the 
transcriptional potential of gene. EREs have been identified and defined using reporter 
systems to test the enhancer ability when exposed to different compounds.46 Also, 
deletional analysis has allowed the definition of the sequence of EREs. Optimally, it 
consists of two inverted repeats separated by any three base pairs. The exact sequence of 
EREs varies between species and genes.47 
Some models of estrogen action predict that when the dimerized hormone- 
receptor complex binds to the palindromic ERE, it forms a looped structure allowing the 
ER to interact with the transcriptional apparatus at the RNA initiation site. It is thought 
that the hormone-receptor complex can recruit components of the transcriptional complex 
and serves as a nucléation site. Previous studies focus on the interaction of the ER with 
EREs, but more recently, there has been a shift toward the study of ER receptor 
interactions with ancillary proteins in the nucleus. 
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Common Chemotherapeutic Agents 
Antiestrogens 
Tamoxifen 1, a nonsteroidal antiestrogen, is the most commonly used 
chemotherapeutic agent for treatment of advanced breast cancer and as adjuvant therapy 
in premenopausal women.49 Currently, tamoxifen ! is ubiquitously used in hormone 
therapy against post menopausal breast cancer. Clinical trials for long term therapy with 
tamoxifen 1 as a preventive measure against breast cancer have demonstrated its 
effectivness.50 Tamoxifen J_ is effective against metastatic breast cancer, delays relapse 
and prolongs survival after primary surgery.51 
1 
Antiestrogens can be classified into two major groups: analogs of tamoxifen 1 or 
its metabolites, 4-Hydroxytamoxifen (4-OHT) 2, which have mixed 
estrogenic/antiestrogenic actions in laboratory assays. 
The triphenylethlyene structure of tamoxifen \ has provided the basis for several 
new analogs that are being investigated in clinics. The finding that tamoxifen is 
metabolized to 4-Hydroxytamoxifen 2, a potent antiestrogen, also has provided a central 
theme for drug development.52 
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The principal tamoxifen analogs currently under investigation are illustrated. 
Toremifene 3, or chlorotamoxifen, has been investigated thoroughly as an antiestrogen 
and antitumor agent in the laboratory, and currently is being used for the treatment of 
advanced breast cancer and is being tested as an adjuvant therapy.53 Toremifene 3 is of 
interest because it does not produce DNA adducts in rat liver and, as a result, is not a 
potent carcinogen in rat liver.54 
CH3 
3 
Idoxifene 4 is a 4-iodopyrrolidino derivative of tamoxifen that has antiestrogenic 
and antitumor properties in laboratory rats.55 Idoxifene 4 is a metabolically stable analog 
of tamoxifen synthesized to avoid toxicity reported with tamoxifen in the rat liver.55 
Substitution of halogens in the 4-Position of tamoxifen is known to reduce antiestrogen 
14 
potency by preventing conversion to 4-OHT,56 and it was argued that reduced 
déméthylation of the side chain also would avoid the formation of formaldehyde in the 
liver. 57 
Droloxifene 5, or 3-hydroxytamoxifen, has been studied extensively as an 
58 antiestrogen and an antitumor agent in the laboratory. This drug does not form DNA 
adducts under laboratory conditions,59 or produce liver tumors in rats.58 Extensive 
clinical testing has shown activity in the treatment of advanced breast cancer in 
postmenopausal patients. 60 
CH, 
TAT-59 6 is a prodrug that is being developed for the treatment of advanced 
breast cancer. TAT-59 6 has been shown to inhibit the growth of ER-positive, DMBA- 
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induced rat mammary carcinomas.61 The drug inhibits the growth of estrogen-stimulated, 
ER-positive breast cancer cells transplanted into athymie mice.62 The drug is activated 
metabolically to a dephosphorylated form61 that binds with high affinity to the ER.63 
Clinical studies using TAT-59 6 for the treatment of advanced breast cancer have not 
been published. 
CH3 
Additionally, compounds are being investigated that do not resemble 
triphenylethylenes but do exploit the known structural requirements for high binding 
affinity for the ER.64 
The compounds LY117018 7 and raloxifene 8 have high binding affinity for the ER but a 
lower estrogenic activity than tamoxifen when using rodent uterine assays.65 They are 
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competitive antagonists of estrogen action but also can block the estrogen-like effects of 
tamoxifen in the uterus.66 This demonstrates a single mechanism of action for this class 
of drugs through the ER. 
Although tamoxifen l has been used successfully to treat approximately 70% of 
all ER-positive tumors, there are some disadvantages involved with its use: 1) an 
increased incidence of endometrial cancer; 2) its mechanism of action almost exclusively 
lends itself to treatment of ER-positive breast tumors; and 3) with constant treatment of 
tamoxifen J_, resistance can develop.67 Side effects from tamoxifen I treatment have been 
observed in clinical trials. Although it increases hot flashes, it may be beneficial in 
preventing coronary heart disease because it lowers low-density lipoprotein cholesterol 
and apolipoprotein B. Not everything under estrogen control is affected by tamoxifen 1, 
for example, bone mass and clotting factors remain unchanged. On the other hand, long 
term treatment with tamoxifen l can induce growth of hormone responsive human breast 
tumor in nude mice. In nude mice with breast tumor and endometrium tumor xenografts, 
treatment with tamoxifen J, results in a decrease in size of the breast tumor, but an 
increase in size of the endometrial tissue.68 Long term exposure to tamoxifen I has no 
effect on the doubling time of the estrogen receptor negative cell line MDA-MB435, but 
it induces the formation of a new tetraploid clone that, when implanted in the flank of 
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nude mice yields a greater tumor mass that has a higher mitotic index and is more 
anaplastic than tumors obtained from wild type MDA-MB435 cells.69 
Other Chemotheraputic Agents 
Genistein 9, a natural flavanone compound found in soy, has been proposed to be 
responsible for the low rate of breast cancer in Asian women. Genistein 9 is a tyrosine 
kinase inhibitor that works by altering the auto-phosphorylation step on the Epidermal 
Growth Factor Receptor (EGFR).70 Genistein 9 is found to exert pronounced 
antiproliferative effects on both ER-positive and ER-negative human breast carcinoma 
cells through G2-M arrest, induction of p21Wafl/CIPl expression, and apotosis.71 
Genistein 9 also suppresses the production of stress proteins in cells; such as heat shock 
proteins and glucose-regulated proteins that normally help cancer cells survive 
72 destruction by the immune system. 
Doxyrubicin 70 is a common chemotherapeutic agent used for treatment of 
various types of cancers including breast cancer.73 It is categorized as an anthracycline 
antibiotic agent that exerts its effect on cancerous and normal cells by binding to the 
DNA through intercalation between specific bases and blocking the synthesis of new 
RNA or DNA (or both). This intercalation causes DNA strands scission, and interferes 
with cell replication.74 
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One of the major problems associated with doxyrubicin K) treatment is toxicity 
symptoms such as myelosuppresion, and cardiac toxicity.75 
Paclitaxel (Taxol9) JT, the prototype taxane, was developed as an anticancer 
agent at an accelerated pace after the elucidation of its unique mechanism of action and 
by the initial demonstration of its activity in refractory advanced ovarian carcinoma. The 
drug functions as a mitotic spindle poison through the enhancement of tubulin 
polymerization. Multidisciplinary efforts to procure sufficient quantities of this agent 
have allowed a rapid expansion of clinical trials.76,77 
Taxotere 12 is an anticancer agent that inhibits cancer cell division by essentially 
“freezing” the cells internal skeleton, which is made up of elements called microtubules. 
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These microtubules assemble and disassemble during the cell cycle, but Taxotere 
promotes the assembly and blocks the disassembly, thus preventing cancer cells from 
dividing. This action can lead to cancer cell death. The observed side-effect is a 
reduction of the white blood cell count.82 
Aredia T3 is used for treatment of patients with osteolytic bone métastasés of 
breast cancer, in conjunction with standard antineoplastic therapy. It exhibits its clinical 
usefulness by inhibiting bone resorbtion. It is particularly useful for the treatment of 
hypercalcemia associated with malignancy. It has been proven to reduce the incidence 
of skeletal complication of metastatic breast cancer. However, the incidence and type of 
adverse events with Aredia were fatigue, fever, nausea, skeletal pain, transient 
78 arthralgias, and myalgias. 
13 
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Arimidex \4 is used for advanced breast cancer in postmenopausal women whose 
disease has progressed following therapy with tamoxifen T Many side effects have been 
reported including asthemia, nausea, hot flashes, pain, and back pain.79 
Navilbine L5 is a chemotheraputic drug available for the treatment of metasttic 
breast cancer. It is indicated for the treatment of patients with metastatic breast cancer 
who have failed standard first-line chemotherapy. Side effects include tingling in fingers 
and toes, constipation, and hair loss.81 
Need for New Drugs 
As stated previously, it is estimated that by the year 2000 the incidence of breast 
cancer will be between 1.1 and 1.4 million new cases per year. The incidence of breast 
cancer has increased substantially over the last 40 years. Breast cancer accounts for 
21 
almost one-third of all new cancer diagnoses in women and almost 20% of cancer-related 
female deaths.2 
Further, as stated previously,multiple chemotherapeutic agents and regimens exist 
with documented antitumor activity against breast cancer; however, less than one in five 
patients with stage IV breast cancer are alive 5 years from the first detection of distant 
métastasés.12 Although improved response have been observed, overall survival for 
patients with metastatic breast cancer has not been significantly improved by the progress 
of the past three decades. Furthermore, despite the proven benefit of adjuvant systemic 
therapy in reducing the risk of recurrence, a significant fraction of patients with early 
stage breast cancer still will relapse and ultimately die of metastatic disease.13 Clearly 
new active agents and strategies are needed to improve upon this situation. 
The major objective of this research was to synthesize and characterize a class of 
novel breast antineoplastic agents that demonstrate higher efficacy and potency for 
various types of breast cancer cell lines without demonstrating high toxicity for normal 
breast epithelial cells. 
CHALCONES 
Chalcone J_6 (l,3-Diphenyl-2-propen-l-one) contains aromatic rings (A and C) 
linked by an olefinic bond and a keto group (B). 
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Derivatives of Chalcone 16 are widely distributed in higher plants, and play a central role 
in the biosynthesis of flavonoids. Chalcone _16 itself is considered to be a flavonoid, 
although its chemical structure is different from that of other flavonoids, which have the 
2-phenyl chromone structure 1783 
Chalcone 16 has a stilbene configuration in which two phenyl groups bracket an a,(3- 
unsaturated carbonyl group. Amongst stilbene derivatives are a variety of synthetic 
compounds, for example tamoxifen I, which bind to steroid hormone receptors. 
Compounds containing the a, (3-unsaturated moiety (a reactive chemical species) have 
been found to bind to receptors that increase the activity of phase II enzymes that 
84 metabolize xenobiotic. 
The similarity between chalcone and tamoxifen is that both exhibit an ene 
functionality that separates the phenyl groups. It is important for the structure to have 
this functionality which is the site for the binding. 
General Biological Activity 
Chalcone j_6 and its derivatives have been shown to exhibit a wide variety of 
biological activities,85 including: antiviral;86 antibacterial;87 antitumor;' 




antibiotic;95 antiparasitic;96 antipeptic ulcer;97 hypotensive/antihypertensive;98 
antispasmodic;99 and anticonvulsant.100 
Anti-tumor Activity 
The vast majority of derivatives of chalcone JJ3 have been shown to inhibit 
lipoxygenase activity and TPA-induced tumor promotion of the mouse epidermis. 101 
Isoliquiritigenin J_8 (4,2’,4’-trihydroxychalcone) is particularly potent in this regard.101 
The biological effects produced by chalcone j6 containing other types of substitutions 
have also been investigated. 
In one such study, (E)-4-[3-(3,5-di-tert-butylphenyl)-3-oxo-l-propenyl]benzoic acid 19 




In another study, (2E)-l-(2,5-dimethoxyphenyl)-3-[4-(dimethylamino)phenyl]-2-methyl- 
2-propen-l-one 20 and related compounds were reported to induce antimitotic activity 
103 against tumor cells in vitro. 
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Lichochalcone A 2J_ has been shown to inhibit tumor promotion in mice as well as 
exhibit antitumor activity against L1210 leukemia and B16 melanoma cells in vivo.104 
More recently, 3’-methyl-3-hydroxychalcone 22 has been reported to be a potent 
inhibitor of proliferation of several lines of malignant human cells in vitro, and to 
suppress TPA-induced tumor promoting activity in mouse skin in vivo. 
OH 
An additional attribute of this chalcone 22 is its capacity to inhibit the binding of 
estradiol to type II estrogen binding sites in HGC-27 cells.105 Thus, several substituted 
chalcones have been shown to have effects such as inhibition of cell proliferation and 
tumor promotion that might endow them with chemopreventive properties.106 
25 
Retenoids 23, N-phenylbenzamide, which are structurally similar to chalcone, 
have been shown to exhibit inhibitory activity against non-small cell lung carcinoma 
(NSCLC).107 
Additionally, certain quinoxalines 24 and quinolines 25 show promise as 
1 OX inhibitors of tumor growth. 
24 25 
Anti Breast Cancer Activity 
Certain derivatives of chalcone _16 and some flavones have shown promise as 
antitumor agents in breast cancer. For example, apigenin 26 and some of its congeners 




6,4’-Dihydroxyflavone 27 has a binding affinity for the ER,1 l0and flavone derivative 28 
(BE-14348B) exhibits strong estrogenic activity."1 
The ER binding affinity and the estrogenic activity were also reported for the 
isoflavone derivative daizein 29.112 
Recently compound (L86-8275) 30 was reported to exhibit antitumor activities against 
several types of human breast cancer cell lines.113 
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Chalcone 16 is widely consumed by herbivorous animals, and it is not toxic. 
Derivatives of chalcone 16 seems to have pharmacological properties such as estrogenic 
activity, inhibition of inflammation and anti-microbe activity, and it has also been 
reported to have an inhibitory effect on tumor growth.114 
1-SUBSTITUTED ADAMANTANE DERIVATIVES 
General Biological Activity 
Many derivatives of adamantane 3J. are biologically active compounds with a 
broad spectrum of activity. The spatial structure, hydrophobicity, and lipophilicity of 
adamantane ensure favorable conditions for its transport through biological membranes. 
The introduction of an adamantyl moiety into organic compounds changes and often 
enhances their biological activities.114 
x 
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In 1966, duPont discovered that amantadine 32 was effective in the treatment of 
influenza A2 in humans. 
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Today, amantadine hydrochloride, the generic name for the prescription drug Symmetrel, 
is known for its pharmacological activity both as an anti-Parkinson and an antiviral drug. 
More recently, rimantadine 33, shown in laboratory tests to be more effective than 
28 
amantadine, has become available in the United States as the prescription drug 
Flumadine.116 
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In addition to antiviral activity, adamantane derivatives have been shown to be 
antimalarial,117 antibacterial,118 anti-Parkinson,119 immunodepressive,119 hypoglycemic,119 
antifungal,119'120 sedative,119'121 anticonvulsant,119,122 antiflammatory,119'123 
antidepressant,124 and anticalaleptic.125 
Anti-tumor Activity 
As stated earlier, many derivatives of adamantane 3J. are biologically active 
compounds with a broad spectrum of activity. However, only a few studies concerning 
the general anti-tumor activity of these compounds could be found in the current 
available literature, as delineated in the following examples. Wang, et al, demonstrated 
that the growth of several cancer cell lines could be inhibited by the in vitro 
administration of adamantyl maleimide 34 and methyladamantyl maleimide 35 l26'127'128 
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Clark, et al, and Takatori et al, observed that the capacity for amantadine 32 and 
its isomer, 2-aminoadamantane 36, to modulate lymphocyte activity depended on the 
location of the subtitutent group on the adamantane 31 derivative.129'130 
Rowlands, et al, have reported that greater reduction of human placental 
aromatase inhibition by the alkoxy of 4-pyridyl esters 37 could be achieved through the 
introduction of greater bulk via substitution with adamantyl. 131 
Zakrezewski, et al, demonstrated that 2,4-diamino-5-adamantyl-6- 
methylpyrimidine 38 was active against both Walker Carcinoma 256 (a methotrexate- 
insensitive tumor) and Murphy Sturm Lymphosarcoma (a methotrexate -sensitive 
tumor).132 
Several other compounds containing the adamantyl moiety have shown anti¬ 
tumor activity.133'134'135'136 
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Anti-Breast Cancer Activity 
Only handful of compounds have been synthesized for treating or preventing 
breast cancer. Moreover, only a few chalcone and flavone derivatives show activity 
against breast cancer. Even fewer compounds containing the adamantane moiety have 
shown activity against breast cancer. An extensive literature review revealed that only 
two compounds containing the adamantane moiety have been reported to exhibit activity 
against breast cancer. These two compounds are: the acid 6-[3-(l-adamantyl)-4- 
hydroxyphenyl]-2-2-Naphthalenecarboxylic Acid (CD437, AHPN) 39^ and the 
corresponding disubstituted admantyl ester, 6-[3-(3,5-dimethyl-l-adamantyl)-4- 
methoxyphenyl]-2-naphthoate 40.137,138 
39 40 
These compounds 33 and 34 have also shown activity against other forms of 
cancer, especially leukemia.139 
To our knowledge no study concerning the anti-breast cancer activity of chalcone 
and chalcone-like derivitives containing the adamantyl moiety has been reported in the 
current available literature. This thesis contains the first reported study specifically 
focused on the activity of chalcone and chalcone-like derivatives containing the 
adamantyl moiety against breast cancers. 
Predicated upon the historical development of adamantane and chalcone 
compounds as viable anticancer agents this work proposed to explore the possibility of 
preparing a series of adamantane derivatives and testing their biological in vitro for breast 
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cancer activity. The purpose of the current study was to synthesize a class of novel breast 
antineoplastic agents (based on structure activity relationships with chalcone compounds) 
that demonstrate higher efficacy and potency for various types of breast cancer cell lines 
without demonstrating high toxicity for normal breast epithelieal cells. Those compounds 
that showed a high level of antiproliferative activity against tested breast cancer cell lines 
but not against normal breast epithelial cells would be evaluated for future in vivo 
antitumor studies. 
The goals of this study were: 
1. To design a group of novel anti cancer agents that have activity against breast 
cancer based on structure activity relationships using existing chalcone 
derivatives; 
2. To synthesize and characterize chalcone-like derivatives with the aromatic A 
ring replaced by the adamantane moiety; 
3. To synthesize and characterize chalcone-like derivatives with modification in 
the B region; 
4. To synthesize and characterize chalcone-like derivatives with modification in 
the C region; 
5. To synthesize and characterize chalcone derivatives with the adamantane 
moiety substituted on the aromatic A ring; and 
6. To conduct in vitro biological screening tests of these novel compounds for 
anti-proliferative activity against established human breast cancer cell lines. 
The work reported in the following sections of this dissertation are an effort to 
achieve the above stated goals. This will be mainly accomplished through evaluating the 
anit-proleferative activity of these novel compounds against available human cancer and 
normal cell lines. 
CHAPTER TWO 
RESULTS AND DISCUSSION 
The synthetic scheme for the series of adamantyl chalcone and chalcone-like 
compounds was to prepare derivatives with structural modifications in three regions of 
the basic chalcone 12 skeleton, (A, B, and C). By altering these basic regions, our 
laboratory was able to examine some of the substituent effect modifications that modulate 
biological activity and change potencies of these compounds towards human breast 
cancer cell lines MCF-7 and MDA-MB435. 
SYNTHESIS AND CHARACTERIZATION 
A total of twenty-four adamantyl chalcone and chalcone-like compounds were 
synthesized and characterized. These compounds were conveniently divided into four 
categories: 1) Series I. Chalcone-like compounds with the aromatic A ring replaced by 
the adamantane moiety; 2) Series II. Chalcone-like compounds with modification in the 
A ring and B regions; 3) Series III. Chalcone-like compounds with the aromatic C ring 
replaced by heterocycle group; and 4) Series IV. Chalcones with the adamantane moiety 
substituted on the aromatic A ring. The synthesis and characterization of each series will 
be discussed in the section that follows. 
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Series I. Synthesis of Chalcone-Likes Compounds 43 with Aromatic A Ring 
Replaced by Adamantane Moiety 
A series of twelve chalcone-like compounds 43 with aromatic A ring replaced by 
the adamantane moiety was prepared by base-catalyzed Aldol condensation of 1- 
adamantyl methyl ketone 44 and substituted benzaldehydes 42 (eq 1). 
1-Adamantyl methyl ketone 44 reacted readily, at ambient temperature, with a variety of 
substituted benzaldehydes 42 in alkaline ethanol to afford the corresponding chalcone 
like compounds 43(a-l) in good yields. Compounds synthesized by this method are 
shown in Table 1. These compounds were synthesized, purified and fully characterized 
by NMR, GC-MS, and Elemental. Analyses. 
Table 1 shows that the percent yield of products tends to be very good to excellent 
regardless of the substituent on the aromatic ring. The ease with which the compounds 
were obtained makes this particular reaction a very convenient method for its application 
in the synthesis of widely varying analogs with potential antineoplastic activity and other 
biological activities. 
Literature reviews and observations in our laboratory suggest that the melting 
points of adamantane derivatives tend to vary by several degrees according to method of 
determination (heating rate, sealed capillary, or cover glass). To ensure consistency 
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melting points were determined on a calibrated programmable Electrothermal 9200 
Melting Apparatus with set point usually 5 °C below predetermined (estimated) melting 
point and a ramp rate of 0.3 °C/min. as shown in Figure 3. This method enabled us to 
determine melting points accurately within one-tenth of a degree. 
Table 1 
Chalcone-Like Compounds 43 Synthesized with Aromatic 
A Ring Replaced by the Adamantane Moiety 
Compd X % YIELD MP°C 
43a H 92 90.1-91.4 
43b p-CN 96 160.1-161.3 
43c p-N02 68 165.0-166.1 
43d p-CI 89 141.8-143.3 
43e p-N(CH3)2 92 155.1-156.2 
43f p-CH(CH3)2 94 93.5-94.9 
43g P-OCH3 96 114.3-115.0 
43h p-F 94 129.8-131.4 
431 o-Br 91 120.3-121.6 
43j p-OCH2Ph 90 132.7-134.7 
43k p-Ph 86 133.6-135.0 
431 P-Et 88 78.3-79.9 
Proton NMR data for Ha and Hb (structure 44) were examined to determine trends 
in chemical shifts as well as to determine the stereochemistry of the double bond. The 
proton NMR chemical shifts (Ô, ppm) and coupling constants (Jab, Hz) for Ha and Hb are 
given in Table 2. 
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Figure 3. Melting point determination on the Electrothermal 9200 
melting point apparatus. 
Table 2 shows that the chemical shift for Hb varies from 6.98 to 8.08 ppm 
depending upon substituent X on the aromatic ring. Electron withdrawing groups tend to 
give signals at lower field (for instance NO2, 7.28; F, 7.64 ppm) whereas electron 
donating groups show signals at higher field (N(CH3)2 6.98, CH(CH3)2 7.15 ppm). 
The values for the coupling constants Jab for protons Ha and Hb are consistent with 
trans stereochemistry. It is widely known that for three-bond proton-proton coupling, the 
coupling constant Jab depends on the dihedral angle (]) between Ha and Hb. This 
dependence of the coupling constant Jab on dihedral angle <j) is described by the well 
known Karplus-Conroy curve140. Fords protons Ha and Hb on a double bond in alkenes, 
the dihedral angle ()) is zero degrees (0°). Similarly, for trans protons Ha and Hb on a 
double bonds in alkenes, the dihedral angle 0 is one hundred and eighty degrees (180°). 
A review of the Karplus-Conroy curve revealed that it predicts larger coupling constants 
for trans Ha and Hb stereochemistry about a double bond in alkenes
140. Consistent with 
the Karplus-Conroy curve prediction, experimental measurements have shown that the 
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coupling constant Jab for çis protons Ha and Hb usually fall within the range of 9-12 Hz, 
while the coupling constant Jab for trans protons Ha and Hb generally fall within the 14-17 
Hz range. The proton coupling constants Jab for Ha and Hb in compounds 43a-l vary from 
15.4 to 15.9 Hz, all within the range for a trans substituted double bond. Therefore, we 
have assigned a trans configuration for these compounds. 
Table 2 
Proton NMR Chemical Shifts and Coupling Constants for Ha and Hb (44) 
Compd x 
Chemical Shift (ppm) Coupling Constant 
Ha Hb 
Ja-tH Hz) 
43a H 7.69 7.18 15.6 
43b p-CN 7.67 7.23 15.6 
43c p-N02 7.68 7.28 15.7 
43d p-CI 7.62 7.14 15.6 
43e p-N(CH3)2 7.67 6.98 15.4 
43f p-CH(CH3)2 7.69 7.15 15.9 
43g P-OCH3 7.65 7.05 15.4 
43h p-F 7.64 - 15.6 
431 o-Br 8.08 7.12 15.7 
43j p-OCH2Ph 7.67 7.07 15.5 
43k p-Ph 7.74 7.23 15.4 
431 P-Et 7.67 7.18 15.5 
Two compounds in this series 43f and 43g were successfully recrystallized for 
crystal structure determination. Crystallographic structures are presented in Figure 4 and 
Figure 5, respectively. The corresponding crystallographic data are presented in 
Appendix A and Appendix B respectively. The crystalline structures obtained for these 
two compounds supported the stereochemical assignment made by the NMR (Table 2). 
As detailed in Appendix A and shown in Figure 4 the conformation of the styrene subunit 
with respect to the carbonyl for 43f is trans with 01-cl-c2-c3 and cl-c2-c3-c4 torsion 
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angle values of -11.8 and 176.0, respectively. Likewise the conformation of the styrene 
subunit with respect to the carbonyl for 43g is trans with 01-cl-c2-c3 and cl-c2-c3-c4 
torsion angle values of -4.7 and 179.4, respectively, as detailed in Appendix B and 
shown in Figure 5. 
Figure 4. Crystal Structure of Compound 43h 
Figure 5. Crystal Structure of Compound 43g 
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The fragmentation pattern is very consistent for all these compounds. The base 
peak observed at m/e 135 (except for the N,N-dimethyl and methoxy derivatives) arises 
from the decomposition of the adamantyl cation. This fragmentation of adamantane is 
very common in 1-susbtituted adamantanes.141 However, the parent peak, if it appears at 
all, is very weak. A scheme of the fragmentation process is shown below. 
m/e 135 
X = Alkyl, NpCl, Br, COOH, COQH 
Series II. Chalcone-Like Compounds 45 with Modification in A and B 
Regions 
A series of three chalcone-like compounds 45 with modification in the A and B 
regions was prepared by based-catalyzed Aldol condensation of 1-adamantyl methyl 
ketone 44, with substituted cinnamaldéhydes 44 in alkaline ethanol at ambient 
temperature to give the corresponding chalcone-like compounds 45 (eq. 3). The percent 
yield and melting points for these compounds 45 are presented in Table 3. 
Table 3 
Chalcone-Like Compounds 45 Synthesized 
with Modification in the A and B Regions 
Compd X Y % YIELD MP°C 
45a OCH3 H 71 188.0-190.0 
45 b H CH3 74 158.8-160.3 
45c H Cl 68 171.2-172.1 
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Series III. Chalcone-Like Compounds 47 with Aromatic C Ring Substituted 
By Heterocvcle group 
A series of eight chalcone-like compounds 47 with modification in the A and C 
ring was synthesized. Due to the proprietary nature of compounds in this series, Het is 
used to represent the heterocyclic group. The reaction was carried out via aldol 
condensation of 1-adamantyl methyl ketone 44 and the heterocyclic aldehyde 46 to afford 
the desire product £7 as shown in (eq 4). The percent yield and melting point for these 
compounds 47 are presented in Table 4. 
Series IV. Synthesis of Chalcones 58 with Adamantane Moiety Substituted 
on Aromatic Ring A 
This series of compounds was prepared to study the effect of the adamantane 
moiety as a substituent on the aromatic A ring. In order to do this we had to prepare the 
appropriate aryl adamantanes prior to carrying out the Aldol condensation. 
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Table 4 
Chalcone-Like Compounds £7 Synthesized with 
Aromatic C Ring Substituted by Heterocyclic Ring 
Compd % YIELD MP°C 
47a 72 94.4-97.5 
47b 81 105.7-106.9 
47c 85 125.7-127.5 
47d 54 119.1-120.3 
47e 64 120.8-122.0 
47 f 71 157.0-159.0 
47g 39 165.0-167.0 
47h 68 197.2-98.3 
Synthesis of Aryl Adamantanes 50 Adamantylation of aromatics has not been 
frequently studied, in spite of its potential importance. Testafari and coworkers studied 
adamantylation of aromatics in a radical reaction with the 1-adamantyl radical to describe 
the effect of substituents on the reactivity and isomer distribution142. Newman first 
reported the AlCh-catalyzed Friedel-Crafts alkylation of benzene with 1- 
bromoadamantane, where a complex product mixture was obtained (eq 5) l43. 
Other _ 
products ’ 
48 49 50 
Later the adamantylation of reactive aromatics with adamantyl nitrate and a FeCL- 
catalyzed reaction was described using an excess of the aromatic compound.144 In the 
case of toluene as substrate exclusive formation of para-adamantylated product was 
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reported.145 The study of Friedel-Crafts adamantylation of benzene and toluene in the 
presence of boron tris(triflate) has also been reported (eq 6).146 
All attempts at adamantylating nitrobenzene were unsuccessful, as expected. The 
nitro substituent is a strong electron withdrawing group thus greatly decreasing the 
reactivity of the aromatic system towards electrophiles. 
Iron filing-catalyzed Friedel-Crafts alkylation of aromatic compounds with 1- 
bromoadamantane 48 is unknown. However, the use of iron as a Friedel-Crafts catalyst 
in alkylation of aromatic systems has been described in the literature.147 In this study, a 
novel methodology for the adamantylation of benzene 49 and some of its derivatives has 
been discovered. One of the most remarkable features of this reaction is the ease of 
product separation from the iron catalyst by simple filtration. Moreover, no usual 
aqueous basic work-up is necessary. 
This particular adamantylation reaction appears to be versatile as to what type of 
catalyst can be used. Iron (0), Iron (II) oxide and iron (III) oxide does give the Friedel- 
Craft products in very good yields. 
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Table 5 
Some 1-Aryladamantanes 54 Synthesized By this Method 
Compd X % YIELD Mp°C 
54a H 90 87.3-88.9 
54b Me 93 95.3-98.9 
54C OMe 95 78.4-81.3 
Given that these Friedel-Crafts type alkylation reactions are expected to proceed 
via cationic intermediates, then it is reasonable to expect Fe to be an effective catalyst. 1- 
aryladamantanes 54 were prepared by heating (boiling temperature of the reacting 
aromatic system) the reaction of 1-bromoadamantane 48 with substituted benzenes 53 in 
the presence of Fe (eq 7). The experimental results show that the reaction rates decrease 
significantly in parallel with the decrease in reaction temperature. The adamantylation 
reaction does not take place at room temperature. 
As evidenced by the experimental data presented in Table 5 this synthesis indeed 
produced very pure product in excellent yields. The mechanism for this reactions appears 
to be ionic as confirmed by the stereochemistry of the Friedel-Crafts alkylation products. 
For instance, electron withdrawing substituents on the aromatic system yield exclusively 
the meta-substituted derivatives, whereas electron donating susbtituents afford the 
corresponding para-substituted products. It is worth noticing that only the para substituted 
isomer is observed. The significant differences in the stability of ortho and para isomers 
can be explained by the strong steric interaction between the ortho substituent and the 
bulky adamantyl group. Thus preventing the formation of the ortho isomer. These 
products were fully characterized by GC-MS, proton and carbon-NMR. The results 
described herein also agree with monoadamatylated products synthesized by Olah et al.148 
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In addition, Engel et al found the formation of bi-adamantane in yields of at least 20% 
when forcing the mechanism to follow the free radical pathway in the presence of AIBN 
and tributyltin.149 These reagents are well known to induce the formation of free radicals. 
In this work, no bi-adamantane was detected thus indicating that mechanism for the Fe 
catalyzed Friedel-Crafts adamantylation proceeds via ionic pathway. 
It is well known that 1-adamantyl cation is a stable bridge-head carbocation.150 
This carbocation is formed by reacting bromoadamantane with a Lewis acid catalyst and 
attacking by the aromatic system in a traditional Friedel-Crafts way. The susbtitution 
pattern will determine whether the mechanism is via a free radical or ionic. A series of 
simple experiments were designed in order to study the stereochemistry of the products 
thus determining the preferred mechanistic pathway. 
Electron donating substituents favor meta substitution on the aromatic ring when 
the reaction is proceeding by a free radical mechanism. In addition, electron withdrawing 
groups favor ortho/para substitution when following similar pathway. However, electron 
donating substituents favor ortho/para substitution and electron withdrawing substituents 
favor meta substitution when the reaction takes place via an ionic mechanism. The results 
shown herein (para adamantylation for electron donating groups on the benzene ring and 
meta adamantylation for electron withdrawing groups). 
A scheme showing the comparison between the two mechanistic pathways is 





Figure 6 Comparison between free radical vs. ionic adamantylation. 
Solid acid catalyzed Friedel-Craft adamantylation reactions have been found to be 
a convenient methodology for the preparation of adamantyl-substituted aromatics with 
high para-regioselectivity. DeMeijere et al. has utilized palladium/charcoal mixed with 
potassium carbonate as catalyst for Friedel-Crafts adamatylation reactions. His team of 
researchers has proved the mechanism for such reaction is ionic. However, the times for 
the reactions to take place tend to be mildly lengthy (from 12 to 24 h) and in some 
instances, regardless of the electronic nature of the substituent on the aromatic system, 
some of the desired products are not formed.151 
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The methodology described in this work makes use of much milder conditions 
affording high yields of adamantylated products. The iron catalyzed Friedel-Crafts 
adamantylation presented herein does have a great advantage over the literature 
procedure due to the facility of handling the reactants, the relatively low prices of the 
starting materials, and the easyness in extracting the final products with high degree of 
purity (in some instances, crystals form after filtration and washings with hexane). An 
example is compound 54c. The crystal structure was determined from crude isolated 
crystals. The ORTEP diagram is shown (Figure 7). 
Figure 7 Crystal structure of compound 54c 
The fragmentation pattern for 1-arylsubstituted adamantanes follows a different 
process than that of 1-alkylsubstituted adamantanes. Usually, and in these cases all three 
compounds follow the same behavior, adamantane fragments itself into an aromatic 
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(benzene) unit losing a C4Hy fragment (m/e 57),
141 thus leaving behind a benzene- 
aromatic fragment as a base peak as shown (eq. 8). 
*C4H9 8) 
m/e 57 
X = C6H5, OH, NH 2, Br, NHCOCH 3 
Synthesis of 5-(l-adamantyl)-2-methoxy Acetophenone 55. This acetophenone 
55 was synthesized from the anisole 54c by Friedel-Crafts acylation prior to preparation 
of the chalcone derivatives by Aldol condensation. Friedel Crafts acylation is known to 
perform well if the substituent is an electron donating group. Compound 54c was 
selected since it best exhibited this quality. 
The 1-aryladamantane 54c was converted to 5-(l-adamantyl)-2-methoxy - 
acetophenone 56 by treatment with acetyl chloride in the presence of AICI3 as a catalyst 
at room temperature (eq. 9) 
Synthesis of the Chalcone 58. After considering that the resonance effect in 
aromatic compounds increase biological activity, chalcone 58 was synthesized. 
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Treatment of the resulting product 55 with biphenyl benzaldehyde 57 as described 
previously to give 58 (eq 10). 
In this study we have synthesized a wide variety of compounds and have 
identified several chalcone-like compounds, which possess growth-inhibitory activity 
against selected breast cancer cell lines. Some of the Chalcone-like compounds (series 
III), which have quite different chemical structures from conventional chalcones, show 
higher activity against breast cancer cell lines than chalcones. Screening of these 
compounds on breast cancer cell lines has been conducted in vitro, and the data are 
presented in the sections that follow. 
EVALUATION OF COMPOUNDS FOR BREAST CANCER ACTIVITY 
Mechanisms of Antiestrogen Action 
The current molecular model of estrogen action provides several potential points 
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Figure 8. The current molecular model of antiestrogen action. 
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Two types of antiestrogens are the analogs of tamoxifen or structural derivatives of the 
triphenylethylene type of drug. All of these compounds are inhibitors of the binding of 
E2 to the ER, but there the similarity ends. Antiestrogens seem to form a receptor 
complex that is converted incompletely to the fully activated form. As a result of the 
imperfect changes in the tertiary structure of the protein, the complex is only partially 
active in initiating the programmed series of events necessary to orchestrate gene 
activation.15-’ 
Studies in vitro demonstrate that very low concentrations of triphenylethylene- 
type antiestrogens can cause a single round of replication in breast cancer cells, but high 
concentrations of these antiestrogens are completely inhibitory.154 It is possible that the 
modest partial estrogen-like action at low concentrations causes the tamoxifen flare that 
sometimes is observed when therapy is started in patients with bony métastasés.155 Once 
steady-state levels of the drug have been achieved (approximately 4 to 8 weeks with 20 
mg/day), symptoms will have disappeared and the patient will experience a response to 
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therapy.156 It is important therefore, to be able to identify tumor flare and not 
prematurely terminate a beneficial therapy. Nevertheless, a recent report has 
demonstrated that clinicians often prematurely terminate antiestrogen treatment based on 
changes in bone scintigraphy misinterpreted as progressive disease.157 Because there are 
toxicological advantages in disease control with antiestrogens, a premature change to 
chemotherapy may be inappropriate. 
Interactions with Estrogen Response Elements 
The interactions of the ER with EREs also depend on the nature of the ligand to 
which it has bound. When the effects of binding of estrogenic and different 
antiestrogenic ligands to an ERE are quantitated, it was found that E2-ER and 4-OHT-ER 
complexes bound a singlet ERE with similar affinity. However, at saturation, 4-OHT- 
ER binds 50% the level of E2-ER binding. When the tandem copies of EREs were 
tested, E2-ER exhibited cooperative binding whereas 4-OHT-ER displayed little or no 
cooperativity. Therefore, specific ligand binding can alter binding affinity of the ER to 
DNA and the amount of receptor that is saturated presumably by inducing different 
conformations in the ER protein. Further studies of the mechanism through which 
antiestrogens antagonize the transcription of estrogen-responsive genes through 
differential binding to EREs show that the flanking sequences and stereoalignment of 
EREs are important.159 
A further investigation of antiestrogenic ligands demonstrated that when 4-OHT- 
ER binds to DNA one molecule of 4-OHT dissociates from the ER dimer.160 Under the 
same conditions, tamoxifen aziridine, which covalently attached to the ER, show a 
binding stoichiometry identical with that of E2-ER, which is one dimeric receptor per 
ERE compared with one monomer of 4-OHT-ER per ERE. When DNA footprinting was 
50 
used to determine ER-ligand binding to adjacent EREs, identical high-affinity binding 
was observed for unliganded dimeric ER or ER bound to E2, 4-OHT, and tamoxifen 
aziridine.161 These results suggest that ligand-induced conformation changes primarily 
affect how the ER interacts with the components of the transcription initiation complex 
thereby mediating transcriptional activation. 
Antiestrogens and the Cell Cycle 
The molecular description of the signal transduction pathway for estrogen and its 
modulation by antiestrogens now raises the question of how the protein complexes switch 
cell replication on and off. During the past twelve years, there have been important 
advances in the understanding of the regulation of the cell cycle via growth factors. 
The first experiments that illustrated the connection between antiestrogens and the 
cell cycle showed that thymidine incoiporation in ER-positive cells was reduced on 
treatment with antiestrogens and that no effect was seen in ER-negative cells.162 
Subsequent studies determined that the arrest of cells occurred in the G1 phase of the cell 
cycle resulting in a lower proportion of cell in S phase.163 Studies using synchronized 
cells demonstrated that antiestrogens could only inhibit the growth of cells that were in 
early to mid G1 phase of the cell cycle. 163 Additionally, Lykkesfeldt and colleagues 
studied the effects of tamoxifen treatment on the cell cycle kinetics of MCF-7 cells. They 
showed that after tamoxifen treatment cells treated with newborn calf serum had an 
elongated G1 transit time whereas estrogen treatment shortened G1 transit time.164 
MCF-7 cells have been used to identify cell cycle regulatory genes that could be 
potential targets for antiestrogen action.165 Cells treated with steroidal and nonsteroidal 
antiestrogens had a significant decrease in cyclin D1 mRNA, which suggests that the G1 
cyclins may be a target of antiestrogens to block entry into the S phase. 
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Similar cell cycle effects are seen using T47D human breast cancer cells. 
Antiestrogens reduced the expression of cyclin D1 activity and cell cycle arrest occurred 
in the G1 phase. All of these effects of the antiestrogen were reversed by E2 treatment.166 
These studies provide a valuable insight into the consequences of estrogen and 
antiestrogen action. However, an important issue is not addressed. The critical question 
is whether the ER controls replication directly by nuclear interactions or via growth 
factor-mediated mechanisms. 
The compounds in this study were evaluated by comparing breast cancer cell lines 
MCF-7 (ER-positive) and MDA-MB435 (ER-negative) with noncancerous breast 
epithelial cells (MCF-10). Those compounds that showed a high level of antiproliferative 
activity against tested breast cancer cell lines, but not against normal breast epithelial 
cells were evaluated for in vitro mechanism of action by looking at their effects against 
cellular growth factors, Epidermal Growth Factor (EGF), and Transforming Growth 
Factor (TGF-alpha). 
Biological activities (anti cancer) were measured under the following conditions: 
1. A dose response curve for compounds, series I, II, III, IV, over a concentration range 
of ImM to InM was prepared in order to detect the doses where possible biological 
activity might exist. Biological activity was determined by relative LC50 values of 
these agents. Those compounds that exhibited significant decreased cell viability 
within the established concentration range parameters were examined for their 
relative biological activity and potency against known antibreast cancer agents 
tamoxifen J_, genistein 9, and doxyrubicin JO. 
2. The compounds in series I, II, III, and IV were examined against two different types 
of breast cancer cell lines which included estrogen receptor positive (MCF-7) and 
estrogen receptor negative (MDA-MB435) cell lines. This examination allowed our 
laboratory to determine whether the novel agents exhibit relative selectivity for 
estrogen stimulated breast cancer cell lines versus estrogen non stimulated breast 
cancer cell lines. 
3. Toxicity of the compounds for normal breast epithelial cells were examined by 
comparing LC50 values in normal breast epithelial cell line (MCF-10) against LC50 
52 
values in cancer cell lines. LC50 is the concentration that is lethal to 50 percent of the 
cells. LC50 values were estimated from a dose response graph. 
4. The possible mechanism of action of these compounds was explored by examining 
the ability of these agents to reverse growth factor stimulated proliferation. The 
ability of these compounds to attenuate EGF and TGF stimulated growth was tested. 
By examining these parameters, our laboratory was able to determine whether these 
novel agents possess any antiproliferative activity against specific breast cancer cell lines 
MCF-7 (ER-positive) and MDA-MB435 (ER-negative) or toxicity towards noncancerous 
breast epithelial (MCF-10). Further, by pursuing this examination our laboratory was 
able to determine to some extent that certain structural modification enhance the 
biological activity and/or potency of these compounds. 
Two human breast cancers cell lines (MCF-7 and MDA-MB435) and a normal 
breast epithelial cell line (MCF-10) were obtained from ATCC (American Type Culture 
Collection) to test against the series of compounds and the data were examined for the 
compounds’ relative antiproliferation profiles. All of these cell lines were derived from 
epithelial tissue. These cell lines were selected because they allowed our laboratory to 
investigate the effects of the compounds in: 1) breast neoplasms whose growth is 
stimulated by the presence of estrogen, MCF-7 (ER-positive); 2) Breast neoplasms whose 
growth is not stimulated by estrogen MDA-MB435 (ER-negative); and 3) A non-cancer 
cell line (MCF-10) to compare relative toxcities of the compounds. 
It has always been difficult to obtain cultures of breast tumor cells from primary 
mammary tumors because the presence of fibroblasts and fatty and lymphocytic tissue 
make it difficult to isolate the mostly epithelia breast tumor cells. Even when such cells 
are isolated, there is only a low number of viable tumor cells in solid tumors. Cell lines 
have been successfully established from pleural effusions, however, pleural effusions 
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arise from metastasizing tumors and are found in the cavity between lung and the chest. 
The fact that the tumors are metastasizing probably indicates the presence of more active 
cells, and the cells in the pleural effusion may somehow have adapted to a liquid 
environment165. 
Most of the human breast cancer cells in continuou culture are of epithelial origin. 
MCF-7 cells were obtained by growing a primary culture from a pleural effusion of a 
patient with an infiltrating ductal carcinoma. This primary culture continuously produced 
free-floating cells that were used to initiate the stable MCF-7 cell line. This cell line 
possesses high affinity for estradiol, which stimulates its growth. It also has the insulin 
receptor but there are conflicting reports about growth induction by insulin168. 
General Screening Results 
The following sections present the findings of the biological screening assays for 
the series I, II, III, and IV compounds. These experiments dealt with non-stimulated cell 
growth and the ability of the synthetic compounds to alter the viability of these cells. 
Series I compounds 
Series I compounds were chalcone like-compounds where the A ring has been 
replaced by the adamantyl moiety. Various concentrations of these compounds were 
added to cancer cell lines and biological activity was measured as detailed in the 
experimental section. 
Series I compounds showed very little effect on the viability of MCF-7 cell, with 
the exception of 43f which exhibited a pronounced effect on cell viability at 
concentrations greater than 10'5 M. At these concentrations, 43f decreased cell viability 
20 percent Figure 9. These series of compounds produced similar effects on MD- 
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MBA435 cells. However, 43f altered cell viability only at much higher concentrations 
than required for MCF-7 cells. (Figure 10). Since these compounds had little impact on 
the viability of cancer cells, no further testing was performed. 
u 
Figure 9 Percent Cell Viability of Selected Compounds From Series I Tested On 
MCF-7 (ER+) Breast Cancer Cell Lines 
IvOg[Conc, M] 
Figure 10 Percent Cell Viability of Selected Compounds From Series I Tested 
On MD MBA-435 (ER-) Breast Cancer Cell Lines 
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Series II compounds 
Series II compounds are chalcone like-compounds with a modification on the A 
ring and the B region, where the A ring has been replaced by the adamantyl moiety and 
the addition of a double bond to the B region. Various concentrations of these 
compounds were added to cancer cell lines and biological activity was measured as 
detailed in the experimental section. 
Series II compounds were not efficacious in altering the viability of MCF-7 cells. 
45a produced a small attenuation in the viability of these cells, while other members of 
these series were in effective. Due to such a finding these compounds were judged 
inappropriate for further testing (Figure 11). 
Figure 11 Percent Cell Viability of Selected Compounds From Series II Tested 
On MCF-7 (ER+) Breast Cancer Cell Lines 
Series III compounds 
Series III compounds are chalcone like-compounds where the A ring has been 
replaced by the adamantyl moiety, and the C ring replaced by a heterocyclic group. A 
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dose response analysis was performed for these compounds to determine their cytotoxic 
properties as specified in the experimental section. 
Five compounds (47a-e) out of twenty-four tested were found to show significant 
anti-cancer activity against the MCF-7 cell lines. The LC50 values for series III (50 pM, 
40 pM, 50 pM, 5 pM, and 0.5 pM respectively) were consistently lower than the LC50 
values of known anti-breast cancer agents: Tamoxifen, Doxyrubicin, and Genestein, 
indicating higher potency (Figure 12). As demonstrated in Figure 14, the compounds in 
series III were consistently more effective at lower concentrations (< 10 pM) than the 
known anti-cancer agents with compounds 47-c and 47-e showing the greatest efficacy. 
Three compounds (47a-c) in series III demonstrated significant anti-cancer activity 
against MDA-MB435 cells, with LC50 values of 1 pM, 5 pM, and 50 pM respectively 
(Figure 15). Known anti-cancer agents tamoxifen and Genestein were measurably less 
potent in MDA-MB435, with LC50 values of 0.5 mM and 5 mM respectively. (No 
measurable LC50 was obtained for Doxorubicin in the concentration range measured). 
These three compounds demonstrated greater activity compared to Doxyrubicin 
and Genestein at concentrations between 10 nM and 0.1 pM, and greater potency at 
higher concentrations (Figure 14). Tamoxifen demonstrated similar activity to our 
synthesized compounds only at concentrations above 0.1 mm, but was ineffective at 
lower concentrations. Compounds 47-d and 47-e proved to be less promising against 
MDA-MB435 cells. For compound 47-e, an LC50 value of ca 5-mM was obtained, for 
compound 47-d, no LC50 value was obtained in the concentration range measured. 








































of 0.5mM and 5mM, respectively). In the concentration range tested, no LC50 was 
obtained for Genestein. 
a) b) 
c) d) 
e) Comparison of the synthesized compounds 
Figure 12. Comparison of the LC50 Values Produced in Human Breast Cancer Line 
MCF-7 cells treated with synthesized compounds (47a-e) and with known anti-cancer 
































Figure 13 Comparison of the LC50 Values Produced in Human Breast Cancer Line 
MDA-MB435 cells treated via treatment with synthesized compounds (47a-e) and with 
known anti-cancer agents Tamoxifen, Genestein, and Doxorubicin 
59 
Figure 14. Comparison of the dose-response % cell death induced in Human 
Breast Cancer Line MCF-7 cells treated via treatment with synthesized 








Figure 15. Comparison of the dose-response % cell death induced in Human Breast 
Cancer Line MDA-MB435 cells treated via treatment with synthesized compounds (47a- 
e) and with known anti-cancer agents Tamoxifen, Genestein, and Doxorubicin 
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The relative toxicity of the synthesized compounds (47a-e) against normal breast 
cells was studied by exposing normal breast epithelial cell line MCF-10 to our 
synthesized compounds in concentration ranges from 1 nM to 1 mM. These cells were 
likewise exposed to equivalent concentrations of Tamoxifen, Genestein, and 
Doxyrubicin. As demonstrated in Figure 16, series III synthesized compounds did not 
significantly decrease the average percent cell viability, which was maintained near one 
hundred percent, at lower concentration of these compounds. At concentrations lower 
than 10'7 M, these compounds appeared to enhance the viability of cells (Figure 16). 
Series IV compound 
Series IV synthesis was chalcone compound where the A ring has an adamantyl 
moiety. This series contained a single compound. A dose response analysis was 
performed for this compound to determine its cytotoxic property as specified in the 
experimental section (Figure 17). This compound showed no biological activity at low 
concentrations, but exhibited a small decrease in cell viability at concentration greater 
than 10'5 with MCF-7 cells. Although one compound was tested in this series, it is 
representative of the structural deign of other members of this series. Due to its inactivity 
at optimal concentrations, no further work was carried out for this compound. 
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Log[Conc, M] 
47a 47b 47c 47d 47c Tam 
(Jen 
figure 16 Dose Response % Cell Viability(control) vs Molar concentration of 
47a-e, Genestein, and Tamoxifen against MCF-10 cells 
figure 17 Percent Cell Viability of 58 Compounds From Series IV Tested On MCF- 
7 (ER+) Breast Cancer Cell Lines 
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Discussion of General Screening Protocol 
Chalcones and isoflavone compounds, such as Genestein, have been cited to 
exhibit anti breast cancer activity, mostly against ER positive breast neoplasms.169 
Antiestrogens, such as tamoxifen, are effective in controlling the growth of estrogen 
receptor positive breast tumors.170 Doxyrubicin, an alkylating agent is a general anti 
cancer drug that can be administered for the treatment of breast cancer.171 
All of these antineoplastic agents were selected as standards to compare with the 
novel chalcone-substituted adamantane compounds (47a-e) for their relative anticancer 
activity against human breast cancer cell lines MCF-7 (ER-positive) and MDA-MB435 
(ER-negative). The compounds were also examined for their relative toxicity against 
normal breast epithelial cell line MCF-10. In order to detect the concentrations at which 
the (47a-e) compounds exhibited an anti breast cancer activity, a concentration response 
curve was generated from ImM to 1 nM. This concentration range was able to give us a 
broad spectrum of ability to decrease the percent of cell viability of the two human breast 
cancer cell lines. 
In the initial evaluation of twenty-four novel adamantane substituted chalcone 
derivatives, five of these compounds exhibited significant anti-breast cancer activity 
against MCF-7 cells, over the tested concentration ranges. Compounds (47a-e) decreased 
the % cell viability of MCF-7 by 50% with LC50 values of 5 mM, I mM, 0.5 mM, 0.5 
mM, and 50 pM, respectively. 47-e (50 pM) proved to be the most potent analog against 
MCF-7 cells compared to the other active analogs. This suggests an important moiety 
modification in the chalcone skeleton structure that can enhance the potency of the 
chalcones-like derivatives. Genestein is an isoflavone that is a precursor to chalcone 
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molecules. Therefore the comparison of (47a-e) compounds to Genestein for anti breast 
cancer activity was paramount. 
The results indicated that the novel (47a-e) compounds were more effective than 
Genestein in increasing the percent cell death of MCF-7 cells (see Figure 14). This 
suggests that the adamantane substitutions were an important modification to the 
chalcone skeleton in terms of enhancing biological activity. LC50 concentrations 
demonstrated that 47-e was more potent than tamoxifen, inducing 50% cell death in 
MCF-7 cells at concentrations of 50 pM and 0.5 mM, respectively. Two compounds, 47; 
ç and 47-d, had comparable LC50 values with tamoxifen. At high concentrations (1 mM) 
all of eight compounds, except 47-b and genestein, induced cell death in excess of 70% in 
MCF-7 cells, indicating potential cytotoxic effects 
Although the LC50 value of 47-e only represented a 10-fold increase in % cell 
death over that obtained for tamoxifen, it nevertheless demonstrated a consistent 
concentration response curve in contrast to tamoxifen’s sudden change in slope. At lower 
concentrations than 1 nM 47-e was significantly more potent than tamoxifen. Compounds 
47-d and 47-c likewise showed a graded response curve, and exceeded tamoxifen potency 
below 0.1 mM. 
Compound 47 e was also found to be more potent than doxorubicien against 
MCF-7 cells at LC5o concentrations of 10 pM and 0.5 mM, respectively. . 47-c and 47-d 
were equally potent as doxorubicien. Doxorubicien has been reported to exhibit general 
anti breast cancer activity, with no specificity for ER-positive vs. ER-negative breast 
cancer neoplasms.172 Therefore, doxorubicin serves as a neutral anti neoplastic agent in 
the in vitro anti breast cancer screening procedure. 
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Compounds 47 a-c,e also were the only compounds out of twenty-four novel 
series agents tested to exhibit anticancer activity against human breast cancer cell line 
MDA-MB435, with LC50 values of 5 pM, 5 pM, 5 pM, and 1 mM, respectively. The anti 
breast cancer activity exibited by 47 a-c against MDA-MB435 cells represented a 1000 
fold increase in potency over both Genestein and Tamoxifen (each with LC50 values of 5 
mM). The third known anticancer agent, Doxorubicin demonstrated no detectable LC50 
value in the concentration range measured. 
These results are not suprising, considering that Genestein is found to be selective 
for estrogen receptor positive breast cancers, and that tamoxifen has been found to induce 
sensitivities toward a subpopulation of ER-positive breast tumors.173 However, based on 
the enhanced potency of these chalcone-like compounds (series III compounds) vs. 
structurally similar Genestein, the substitutions of adamantane moieties indicate an 
important substitution in designing potential anti breast cancer agents with chalcone like 
skeleton structures. 
By LC5o values, 47e demonstrated a significant decrease in percent cell viability 
against MDA-MB435 cells compared to its efficacy towards MCF-7 cells. Also, 47d 
caused a significant decrease in percent cell viability in MDA-MB435 cells as compared 
to MCF-7 cells, with undetectable LC50 values in the tested concentration ranges. These 
significant changes in specificity for ER-positive and ER-negative human breast tumors 
could represent important structural modifications with chalcone skeletal structures that 
changes allows this group of chalcones to be directed towards ER-negative vs. ER- 
positive breast neoplasms. 
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Compounds 47 a-e were all tested for their relative toxicities against a normal 
breast epithelial cell line MCF-10. At the highest concentrations tested (ImM), none of 
the series III compounds decreased the % cell viability of MCF-10 cells below 80% with 
average values of 103, 124, 102, 94, and 98, respectively. This effect demonstrates the 
selective ability of these novel compounds to significantly effect the growth of cancer 
cells without interrupting the mechanisms involved with proliferation of normal breast 
epithelial cells. 
In summary, the results indicated that the novel chalcone-like compounds (47a-e) 
significantly increased (p < 0.01) the cell death of both human breast cancer cell lines 
MCF-7 (ER-positive), and MDA-MB435 (ER-negative), without altering the viability of 
normal breast epithelial cell line MCF-10. 
Antiestrogens and Growth Factors 
During the past 20 years, considerable focus has been put on the mechanisms 
whereby cells modulate the growth stimulus or stop growing when the task of replication 
is complete. The identification of families of stimulatory or inhibitory growth factors that 
affect the same cell (autocrine factors) or adjacent cells (paracrine factors) has 
revolutionized the concepts of hormonal regulation. The ideas have been translated 
during the past decade from general physiology to be applied to cancer control.174 
Transforming Growth Factor a 
Estrogen is believed to increase the production of TGFa and, through autocrine 
activation of the epidermal growth factor receptor, encourage replication. However, 
TGFa alone cannot substitute for estrogen. MCF-7 cell transfected with the cDNA for 
TGFa are not tumorigenic in athymie mice.175 
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Studies by Wakeling and colleagues compared the ability the antiestrogen 
tamoxifen or its active metabolite, 4-OHT, to attenuate the stimulatory effects of TGFa 
on MCF-7 cells.176 They showed that when MCF-7 cells are treated with TGFa, 
tomaxifen partially blocks the stimulatory effect in the absence of E2. In contrast, studies 
using EGF instead of TGFa showed that antiestrogens could not block the actions of the 
growth factor,177 and also that antiestrogens could not block the paracrine influence of 
ER-negative cells from stimulating MCF-7 cells in vitro.178 In addition, it is known that 
estrogens can induce the expression of TGFa in estrogen-responsive breast cancer cell 
lines, whereas antiestrogens generally decrease TGFa expression in vitro and in vivo.179 
TGFa apparently is essential for estrogen-stimulated, anchorage-independent 
growth. TGFa or epidermal growth factor receptor antibodies can negate the E2- 
stimulated, anchorage-independent growth of MCF-7 cells on soft agar.180 The 
antibodies did not affect progesterone or prolactin. 
The effects of antiestrogens on TGFa expression in vivo have not been studied 
extensively; however, one study shows that tamoxifen is capable of down-regulating 
tumor TGFa expression in postmenopausal women with ER-and PR-positive disease but 
not in women with ER-and PR-negative disease.181 
The regulation of TGFa remains unclear. A few putative half-site EREs have 
been identified in the promotor region of the TGFa gene, but other sites in the promotor 
region are required for gene activation182 Constructs of the EREs alone do not appear to 
respond to estrogen action unless the cells are super-transfected with ER.183 By contrast, 
ER-negative cells that are stably transfected with ER184 will induce TGFa mRNA in 
185 response to estrogen. 
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Perhaps, most interesting is the effect of antiestrogens. Raloxifene acquires the 
ability to initiate TGFa synthesis when ER-negative cells are stably transfected with a 
351-mutant ER.186 However, in ER-negative transfectants containing wild-type ER, 
raloxifene is a complete antiestrogen. 4-OHT acts as an estrogen (induction of TGFa) in 
both wild-type and mutant ER stable transfectants.187 Because antiestrogens produce 
different effects in transfectants expressing wild-type or mutant ER, and because 4-OHT 
and estrogen can both initiate TGFa mRNA transcription equally, this provides a unique 
model to determine which proteins associate with the antiestrogen-ERE complex to make 
it so promiscuous. 
Transforming Growth Factor (3 
The TGFP family of inhibitory polypeptides consists of three or more 25 kDa 
members, which are able to homo-or heterodimerize to form complexes that interact with 
the TGF(3 receptor (TGFpR). These peptides are implicated in breast cancer and have 
been found to be over-expressed and correlate with tumor progression.188 TGF(3 binds to 
any of the different characterized TGF(3Rs. The receptor consists of a heterodimeric 
complex, one part of which is a binding protein that is unable to signal and another part 
that is believed to transduce signals to the cell through serine-threonin kinase activity.189 
The ability of TGF(3 to promote tumor progression is counterintuitive because TGFP 
usually produces either growth inhibition or differentiation, neither of which are involved 
in tumor progression. Further study clearly is needed in vivo to determine what 
cooperating factors dictate the effects of TGFP on different cell types, because the results 
may be critical to understanding the success or failure of antiestrogen therapy. 
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The effect of tamoxifen on the production of TGFP is an area of great interest. 
Elucidation of a mechanism could provide an explanation for the cell cycle effects of 
tamoxifen in ER-positive cells and also provide an explanation for the sporadic reports of 
the success of tamoxifen treatment in ER-negative breast cancer. Much work has been 
completed in cell culture but there are important translational aspects of the research that 
are relevant in understanding the action of tamoxifen. 
Tamoxifen has a direct effect on the productionof TGFP in breast cancer cells. 
TGFp expression increases in MCF-7 cells, and further study has shown a differential 
activation of members of the TGFP family.190 However, the results are variable. Some 
studies report an increase in TGFP-2 with tamoxifen,191 whereas others demonstrate rises 
in TGFP-1.192 This observation has been translated to the clinic. Patients that respond to 
tamoxifen therapy show increases in TGFP-2 plasma levels. Knabbe’s study suggests 
that the results of measuring either TGFP-1 levels (which transcriptionally activates 
TGFp-2) or TGFP-2 in the plasma can be used as a predictive test for the efficacy of 
tamoxifen therapy.193 
Some support for the central role of TGFP-2 comes from sampling tumors 
directly. When TGFP mRNA levels from ER-positive breast tumors were monitored 
before and during tamoxifen therapy, the results were variable. Changes in TGFP-1 and 
TGFP-2 did not correlate with tamoxifen treatment, but there was a significant 
correlation between treatment and changes in TGFP-2 in some tumors. The authors 
concluded that response to tamoxifen therapy might be mediated through an increase in 
the expression of a particular TGFP iso-form.194 
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The effect of tamoxifen on ER-negative tumors is far more controversial. Perry 
and coworkers have compared and contrasted the effect of tamoxifen on the induction of 
TGF(3-1 in an ER-positive and an ER-negative cell line.195 After long-term treatment, the 
expression of TGF$-1 increased, independent of ER status, but an accumulation of cells 
in G 1/GO and an increase in apoptosis occurred concurrently. This conclusion tends to 
support a model of the direct effect of tamoxifen on ER-negative cells. 
By contrast, it is possible that the growth of an ER-negative cell is controlled by a 
paracrine mechanism. Perhaps the ER-positive cell produces TGF(3 in response to 
tamoxifen, but the secreted growth factor stops the growth of the adjacent ER-negative 
cells.190 It is known that ER-negative breast cancer cells have a high density of TGF(3 
receptors, and the cells respond to TGF(3 by growth inhibition.196 The hypothesis that an 
ER-positive cell can control the growth of ER-negative cells during tamoxifen therapy 
has been demonstrated in vitro.190 However, this has not been possible to test in animal 
models. Different mixes of ER-positive and ER-negative cells were inoculated into 
athymie animals and treated with the antiestrogen toremifene.197 Regrettably, in model, 
the antiestrogen was unable to control heterogeneous tumor growth. 
However, the laboratory finding that tamoxifen can induce TGF(3 in fibroblasts 
has introduced a new mechanistic dimension to understand the control of ER-negative 
disease by tamoxifen.198 Clearly, if TGF(3 can be induced in the supporting stromal cells 
of a breast cancer tumor during tamoxifen therapy, the paracrine growth inhibitor could 
control the proliferation of ER-negative cells. Butta and coworkers found that TGF(3 
production increases in stromal cells during tamoxifen therapy.199 Although these data 
illustrate that a complex cellular conversation occurs to regulate cell growth, the fact that 
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tamoxifen is not usually successful in ER-negative disease means that the pathways are 
not necessarily dominant. Nevertheless, the realization that TGF(3 can act both as a 
growth inhibitor and as a growth stimulator may ultimately make the pathways important 
to explain tamoxifen failure. 
In summary, the past decade has seen an elucidation of the role of both positive 
and negative growth factors in estrogen-stimulated growth. Although each effect of 
tamoxifen on the growth factor system may in itself be small, it is possible that the 
combined actions of tamoxifen are responsible for the benefits documented with 
tamoxifen in clinical practice. 
Screening Using the Growth Factor Protocol 
The mechanism of the specificity for breast cancer cells vs. normal breast 
epithelial cells has not been established. In order to elucidate the mechanisms, by which 
these novel series III compounds were able to exert their effects against both MCF-7 and 
MDA-MB435 cells, the two cells were examined for common receptors that might be 
involved in cell proliferation. It is known that both cell lines expressed epidermal growth 
factor receptors (EGFR). Also both cell lines are sensitive to epidermal growth factor 
(EGF) ligands and Transforming Growth Factor alpha (TGF-a).200 
There have been several studies that have examined the relative changes in 
expression of EGF, EGFR, and TGF-a in estrogen receptor positive vs. estrogen receptor 
negative breast cancer cell lines.201 These changes in growth factor expression were 
correlated with the stimulation or inhibition of cellular proliferation. Also there have 
been several studies that demonstrate that the isoflavone class of compounds exert their 
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anti breast cancer effects by altering the EGF, and EGFR proteins.203 Because of the 
structural similarity of these isoflavones and chalcones to naturally occuring estrogens, it 
was initially suggested that these isoflavones might prevent hormone-dependent breast 
and prostate cancers by virtue of their potential estrogen-antagonist activity.204 Human 
breast cancer (MCF-7) cells, when placed ectopically in ovariectomized adult rats, grew 
at a faster rate in rats fed genestien-containing diets than in those fed control diets,205 yet 
another indication of the estrogenic activity of genistein. 
In cell culture, genistein inhibited proliferation of human breast and prostate 
cancer cells stimulated by epidermal growth factor (EGF) independently of whether the 
cells expressed estrogen receptors.200 In the presence of 17p-estradiol, genistein induced 
no additional proliferation at any concentration examined.207 Instead, at concentration >5 
pmol/L it caused a dose-dependent reduction in the 17(3-estradiol-stimulated cell 
proliferation.207 These data indicated that genistein may inhibit cell proliferation by 
mechanisms other than classical estrogen-receptor-mediated pathway. Genistein cannot, 
therefore, be viewed simply as either an agonist or antagonist of estrogen. Understanding 
the biological effects of genistein in vivo also requires an appreciation of all of its 
mechanisms of action. Therefore, the novel series III compounds were evaluated for 
their relative abilities to reverse the growth stimulatory effects of EGF and TGF. 
Concentration of genistein that inhibit proliferation of human breast cell lines do 
not effect phosphorylation of EGFR or other target proteins which are normally 
stimulated by EGF.206 Normal human mammary epithelial (HME) cells (which do not 
express estrogen receptor) stimulated by EGF are exquisitely sensitive to growth 
inhibition by genistein without any inhibition of EGF-R tyrosine autophosphorylation; 
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the concentration at which cell growth is inhibited by 50% (IC50) is 1 pmol/L.208 These 
data strongly suggest that genistein affects these cells (and therefore other systems) by 
mechanisms other than inhibition of PTK activity. 
In a glioblastoma model in vitro, both invasiveness and proliferation of 
glioblastoma cells were dependent on EGF, but the invasiveness was blocked by 
genistein at concentrations that did not affect proliferation or EGF-R 
autophosphorylation.200 These data provide compelling evidence of 2 subsets of 
activities modulated by EGF-R, only one of which is affected by genistein. 
EGF & TGF-oc stimulated Growth of MCF-7 and MDA-MB 435 
Both MCF-7 and MDA-MB435 cells contain EGF-R and TGF-R. In an effort to 
examine the role of EGF-R and TGF-R in the proliferation of MCF-7 and MDA-MB435, 
these cells were stimulated to growth stimulatory at 50 percent (GS5o) values. The cells 
were treated with the synthesized compound 47 a at concentrations ranges of 10"9 to 10'3 
M. 
EGF-Serum and non-Serum stimulated growth of MCF-7 cells 
The results indicated that EGF-serum stimulated growth of MCF-7 cells was 
significantly (p<0.02) reversed back to control values by 47 a at 10 pM (figure 18). 
EGF-non serum stimulated growth was also significantly (p<0.102) reversed back to 
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Figure 18 Effectiveness of 47a for reducing EGF(lng/ml)+Serum- 
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Figure 19 Effectiveness of 47a for reducing EGF(lng/ml)+Non Serum- 
Stimulated Growth of MCF-7 Cells 
74 
TGF-a Serum and non-Serum Stimulated Growth of MCF-7 Cells 
The next experiment was performed to examine the possible role of TGF-a in the 
proliferation of MCF-7 cells. The results indicated that neither TGF-a serum stimulated 
nor non-serum stimulated growth of MCF-7 cells significantly reversed by 47a at 
concentration ranges of 10'9 to 10'3 M. 
In evaluating the ability of 47a to inhibit the EGF growth stimulation of MCF-7 
cells, compound 47a significantly reversed the growth stimulatory effects of EGF, but not 
TGF-a. 
-9 -8 -7 6 -5 -4 -3 
Log[Conc, M] 
Figure 20 Effectiveness of 47a for reducing TGF(lng/ml)+Serum- 
Stimulated Growth of MCF-7 Cells 
This could possibly indicate a selective mechanism by which this drug exerts its 
inhibitory effects against MCF-7 cells. The results indicate that the EGF serum (figure 
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20) and non-serum (figure 21) stimulated growth of MCF-7 cells were inhibited by 47a in 
a similar manner. This could indicate that the inhibition seen by EGF-serum stimulated 
growth was mainly due to inhibition of EGF-stimulation. The fact that there was little or 
no reversal on TGF-a serum or non-serum growth stimulation indicates the selectivity of 

























Figure 21 Effectiveness of 47a for reducing TGF(lng/ml)+Non Serum- 
Stimulated Growth of MCF-7 Cells 
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TGF-oc and EGF Serum and non-Serum Growth Stimulation of MDA-MB 435 
Cells. 
Compound 47a was evaluated for its relative ability to reverse the GS50 
stimulation of MDA-MB 435 cells by TGF (lng/ml). The results indicated that the TGF 
significantly (p < 0.02) reversed the serum and non-serum stimulated growth of MDA- 
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Figure 22 Effectiveness of 47a for reducing EGF(lng/ml)+Serum- 
Stimulated Growth of MDA-MB435 
Neither EGF (1 ng/ml) serum nor non-serum stimulated growth of MDA-MB435 cells 
was reversed by to control values at concentration ranges of 10‘y to 10"3 M. This data 
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Figure 23 Effectiveness of 47a for reducing EGF(lng/ml)+Non Serum-Stimulated 
Growth of MDA-MB435 Cells 
Comparing the TGF-a serum to non-serum profiles seems to imply that 47a is able to 
decrease the cell viability of MDA-MB435 cells by interfering with the TGF-a mediated 
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Figure 24 Effectiveness of 47a for reducing TGF(lng/ml)+Serum- 
Stimulated Growth of MDA-MB435 
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The data seems to suggest that one of the possible mechanisms by which 47a 
might decrease the cell viabilities of the two human breast cancer cell lines is to reverse 
the epithelial growth stimulatory effects induced by growth factors EGF and TGF-a. 
Fiterature suggest that these factors play a key role in the proliferation of epithelial 
cells.210 At concentration ranges of 1.00 to 50 pM, the compound 47a reversal effects 
back to control values correlate with LC50 values obtained by drug treatment. Although 
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Figure 25 Effectiveness of 47a for reducing TGF(lng/ml)+Non Serum- 
Stimulated Growth of MDA-MB435 
compounds exert their effects on the human breast cancer cell lines, but they approximate 
a quantitative possibility for their relative mechanism of action. 
We believe that alterations in EGF-R stimulation is a key mechanism by which 
series III compounds decrease the cell viability of MCF-7 cells. This is in agreement 
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with current literature, which indicates an important connection between estrogen and 









Figure 26 Percent Cell Vi ability (control) of 47 a-e Tamoxifen. Doxorubicin, and 
Genestein Against MCF-7 cells at ImM 
In an effort to elucidate possible mechanisms of action that our synthesized 
compounds exhibited against MCF-7 and MDA-MB435 breast cancer cell lines, 47a (the 
parent compound) was evaluated for its relative ability to reverse the growth stimulation 
at 50% of MCF-7 and MDA-MB435 cells by serum and non-serum stimulated epidermal 
growth factor (EGF), and by serum and non-serum stimulated transforming growth factor 
(TGF-a). In all cases 10 ml of growth factor was administered at a concentration of 1 
ng/ml. As demonstrated in Figure 18 through Figure 25, compound 47a was found to be 
consistently effective in reversing the growth of both cell lines. The reversal values are 
summarized in Table 6. 
80 
Table 6 
LC50 Data for Administered Drug 
Cell Line Growth Factor Serum Stimulated Non-Serum Stimulated 
MCF-7 EGF 1 pM 5 pM 
TGF 5 pM 50 pM 
MDA-MB435 EGF 5 Mm 7mM 
TGF 1 pM 2 pM 
Based on these preliminary results, the data indicated that a group of novel chalcone-like 
compounds were synthesized that exhibited a broad range of anti-cancer activity with 
significant reductions in cell viabilities against both human breast cancer cell lines MCF- 
7 and MDA-MB435. Only compounds (47a-e) were found to be active against the above 
cell lines. These agents were found to as potent, and in some cases, more potent than 
known anti-breast cancer agents. These compounds exhibited the ability to reverse the 
stimulatory effects of known tyrosine kinases EGF and TGF a. This suggests that (47a- 
e) compounds might be exerting their anti-cancer effects against MCF-7 and MDA- 
MB435 cells by blocking the growth stimulatory effects of EGF and/or TGF a. These 
results indicate the importance of structural modifications of chemically similar drugs 
towards improving the efficiency and potency of potential antineoplastic agents. 
Genistein’s effects on cells, including inhibition of proliferation, induction of 
differentiation,211 apoptosis,212 and arrest of cells at cell cycle checkpoints213 are 
reminiscent of those of TGF|3l. This peptide growth factor was identified as a major 
factor that regulates eukaryotic cell proliferation by attenuating passage through cell 
cycle check-points.214 Exposure to genistein caused either synthesis and secretion of 
TGFpi by the HME cells or secretion of the preexisting intracellular pool of TGFfH. 
The growth inhibitory effects of tamoxifen were nearly identical to those of genistein 
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involving TGF(3l on the growth of human breast cancer MCF-7 cells. For both 
compounds, the inhibition of cell proliferation was correlated with increased amounts of 
TGF(3l in the culture medium and was blocked by antibodies against TGFpi added 
exogenously to the culture medium. We did not test for the effect of these novel 
compounds on TGFpi, but suggest that these tests should be investigated. 
CONCLUSION 
We have identified novel potential anti-breast cancer compounds, which should 
be inexpensive to produce using the convenient procedure that we have developed. 
According to the biological screening data, we might expect those chalcone-like 
derivatives with hydroxyl group functionality on the C ring or with other substitutions on 
the A ring to be even better anti-cancer drugs. Recently, we have begun development of 
methodologies for the synthesis of chalcones and chalcones-like analogue libraries. A 
total of twenty four adamantyl chalcone and chalcone-like compounds were synthesized 
and characterized. These compounds were conveniently divided into four categories: 1) 
Series I. Chalcone-like compounds with the aromatic A ring replaced by the adamantane 
moiety; 2) Series II. Chalcone-like compounds with modification in the A ring and B 
region; 3) Series III. Chalcone-like compounds with the aromatic C ring replaced by 
heterocycle group; and 4) Series IV. Chalcone with the adamantane moiety substituted on 
the aromatic A ring. The Aldol condensation method was used as a convenient way to 
modify the chalcone structure. Iron filings were used as a catalyst in a new synthetic 
method for the adamantylation of benzene derivatives. This new method provided for 
easy separation and afforded high percent yield of product. These compounds were 




In vitro cell viability studies of novel chalcone like (series III compounds) agents 
proved to be effective anticancer agents against estrogen receptor positive cell line MCF- 
7. Compounds in series III, 47 a-e, exhibited the ability to decrease the % cell viability of 
MCF-7 cells with LC50 values of 5xl0'3m, lxlO'3m, 5xl0'4m, 5xI0"4 m, and lxlO'5m, 
respectively. These values are effective because the active compunds (47 a-e) did not 
significantly decrease the % cell viability of normal breast epithelial cell line MCF-10 
with average % cell viablities of 103, 124, 102, 94, and 98 respectively. 
Compounds 47 a-e proved to be much more effective anticancer agents against 
estrogen negative breast cancer cell line MDA-MB435 cells with LC50 values of 1x10' 
5m, lxl0’5m, 5xl0"ûm, not detectable, and lxl0'3m, respectively. Compound 47 c 
seemed to be the most potent compound in series III. These compounds were also 
considered to be very effective agents because of the lower LC50 values and their relative 
non-toxic effects against normal epithelial cells. 
The novel compounds in series III compounds were examined for mechanism of 
action by evaluating their abilities to reverse the growth stimulation (GS50) at 50% 
induced by EGF and TGF-a. The data indicated that EGF was the most important 
growth factor associated with cellular proliferation of MCF-7 cells (estrogen receptor 
positive). TGF-a was the most important growth factor associated with cellular 
proliferation in MDA-MB435 cells (estrogen receptor negative). 
These active series III compounds can potentially be tested in other breast cancer 
cell lines in order to examine their capabilities to be effective anti breast cancer agents in 
various derived breast neoplasms. Additional tests using other cell lines are being 
performed at the National Cancer Institute (NCI) on a compound from series I to 
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determine its effectiveness against other human cancer cell lines. To date, this compound 
has been shown to have high activity against lung cancer cell line (92% growth inhibition 
at concentration lxlO"4 M) and breast cancer (98% growth inhibition at concentration 
lxlO'4 M). Additionally, biological testing remains to be done on the other compounds 
from series III. 
The methodology has promise for the development and production of many other 




Unless otherwise noted, all starting materials were obtained from commercial 
suppliers and used without further purification. Reactions were monitored by thin-layer 
chromatography (TLC) using precoated glass plates of 250-/im thickness silica gel with a 
fluorescent indicator. Flash chromatography was carried out by using silica gel (35-70 
^m, 60-A pore) or Florisil (100-200 mesh, Fisher Scientific). All melting points were 
determined in sealed tubes on an Electrothermal Digital melting point apparatus, and are 
uncorrected. Elemental analyses were obtained from Atlantic Micro Lab, Inc. (Norcross, 
GA) and are within ± 0.5 of the theoretical values. Infrared spectra were recorded on a 
Nicolet 510 FT-IR spectrometer. Mass spectral data were obtained on a Hewlett Packard 
GC/MS Spectrometer Model HP 6890 at 70 eV. 'H NMR spectra were recorded as 
solutions in CDCI3 on a Varian 200 MHz or Bruker 400 MHz Spectrometer. Chemical 
shifts are expressed in parts per million (5 units) relative to internal tetramethylsilane (0.0 
8) or CHCI3 (7.26 8). Data are reported as follows: chemical shift, multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constant (s), and 
integration. I3C NMR spectra were determined as solutions in CDCI3 on a Varian 200 
MHz or Bruker 400 MHz Spectrometer, and chemical shifts are reported in parts per 
million (8 units) relative to the center peak of CDCI3 (77.0 8). 
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Synthesis of Series I. Chalcone-Like Compounds 43 with Aromatic A Rine 
Replaced by Adamantane Moiety 
Chalcone-Like Compounds 43. A reaction mixture containing adamantyl 
methyl ketone 44 (2.00 g, 11.2 mmol), sodium hydroxide (0.67 g, 16.8 mmol), 
substituted benzaldehyde 42 (11.2 mmol) and ethanol (40 mL) was stirred over night at 
ambient temperature. The reaction mixture was then poured onto crushed ice and stirred 
until it reached room temperature. The precipitate was collected, washed several times 
with water, and air-dried to give 43. Recrystallization from ethanol gave pure product. 
Percent yield and melting point data for 43 are given in Table 1. Elemental analysis and 
GC-MS data for compounds 43 are given in Table 7 and Table 8, respectively. NMR 
data for compounds 43 are reported in Appendix B. 
Table 7 
Series I. Elemental Analysis 
Data for Chalcone-Like Compounds 43 
Synthesized with Aromatic A Ring Replaced by the Adamantane Moiety 
Compd 
Anal. Calcd Y Calculated Found 
For C H N C H N 
43a C19H22O H 85.72 8.26 85.48 8.30 
43b C20H21 NO p-CN 82.49 7.21 4.81 82.57 7.30 4.75 
43c C19H21NO3 p-N02 73.33 6.75 4.50 73.27 6.77 4.51 
43d G19H21 CIO p-CI 75.89 6.98 75.97 6.99 
43e C2,H27NO p-N(CH3)2 81.57 8.73 4.53 81.50 8.81 4.47 
43f C22H280 p-CH(CH3)2 85.72 9.08 85.72 9.20 
43g C20H24O2 P-OCH3 81.09 8.10 81.21 8.15 
43h C19B21FO p-F 80.29 7.39 80.06 7.43 
43j C19H21 BrO o-Br 66.12 6.09 66.06 6.16 
43k C26H28O2 m-OCH2Ph 83.83 7.58 84.08 7.65 
431 C26H28O2 p-OCH2Ph 83.83 7.58 83.98 7.63 
43m C25H260 p-Ph 87.68 7.65 85.09 7.40 
43n C21H260 p-CH2CH3 85.67 8.90 84.39 8.90 
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Table 8 
Series I. GC-MS Data for Chalcone-Like Compounds 43 







Base Peak Molec. Ion 
43a C19H22O 135 266 266 
43b C20H21NO 135 291 291 
43c C19H21NO3 135 311 311 
43d O19H21OIO 135 300 300 
43e C21H27NO 174 309 309 
43 f C22H28O 135 308 308 
43g C20H24O2 161 296 296 
43h C19H21FO 135 284 284 
431 C19H21 BrO 135 345 345 
43j C26H28O2 135 372 372 
43k C26H28O2 135 372 372 
431 C25H260 135 342 342 
43 m C21H260 135 294 294 
Synthesis of Series II. Chalcone-Like Compounds 45 with Modification in A 
and B Regions. 
Chalcone-Like Compounds 45. A mixture of adamantyl methyl ketone 41 (2.00 
g, 11.2 mmol), sodium hydroxide (0.67 g, 16.8 mmol) and substituted cinnamaldéhyde 44 
(11.2 mmol), in of ethanol (50 ml) was allowed to stir overnight at room temperature. 
The reaction mixture was poured into ice water and a solid formed. The product was 
collected and recrystallized from ethanol to give 45. Melting point and percent yields are 
listed in Table 3. Elemental analysis and GC-MS data for these compounds 45 are shown 
in Table 9and Table lOrespectively. NMR data for 45 are shown in Appendix D. 
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Table 9 
Series II. Elemental Analysis Data For Chalcone-Like Compounds 45 
Synthesized with Modifications in A and B Regions 
Compd 
Anal. Calcd Calculated Found 
For 
X Y 
C H C H 
45a C22H26O H CH3 86.23 8.55 86 8.6 
45b 021 H23CIO H Cl 77.17 7.09 77.24 7.14 
45c C22H26O2 OCH3 (0) H 81.95 8.13 81.70 8.24 
Table 10 
Series II. GC-MS Data For Chalcone-Like Compounds 45 
Synthesized with Modifications in A and B Regions 
Molecular Weight 
Compd Molecular Formula Found 
Calculated 
Base Peak Molec. Ion 
45a C22H26O 135 306 306 
45b C2I H23CIO 135 326 327 
45c C22H26O2 135 322 322 
Synthesis of Series III. Chalcone-Like Compounds 47 with Modification in A 
and C Regions. 
Chalcone-Like Compounds 47. A mixture of adamantyl methyl ketone 35 (2.00 
g, 11.2 mmol), sodium hydroxide (0.67 g, 16.8 mmol) and substituted heterocyclic 
aldehyde. 40 (11.2 mmol), in of ethanol (30 ml) was allowed to stir overnight at room 
temperature. The reaction mixture was poured into ice water and a solid formed. The 
product was collected and recrystallized from ethanol to give 47. Melting point and 
percent yield are listed in Table 4. Elemental analysis and GC-MS data for these 
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compounds are shown in Table 11 and Table 12 respectively. NMR data for 47 are 
shown in Appendix E 
Table 11 
Series III. Elemental Analysis Data for Chalcone-Like Compounds £7 with 
Aromatic C Ring Substituted by Heterocycle Ring 
Compd Anal. Calcd For 
Calculated Found 
C H N C H N 
47a C19H21 NO 80.86 7.92 5.24 80.94 7.99 5.05 
47b C19H21NO 80.86 7.92 5.24 81.03 8.05 5.08 
47c C19H21 NO 80.86 7.92 5.24 80.82 7.87 5.36 
47d C19H23NO 81.10 8.24 4.98 81.24 8.34 5.04 
47e C22H23NO 83.24 7.30 4.41 83.01 7.29 4.39 
47f C22H23NO 83.24 7.30 4.41 82.96 7.41 4.32 
47£ C22H23NO 83.24 7.30 4.41 82.97 7.25 4.42 
47 h C17H20OS 74.96 7.40 74.83 7.43 
Table 12 
Series III. GC-MS Data for Chalcone-Like Compounds £7 with Aromatic C Ring 
Substituted by Heterocycle Ring 
Molecular Weight 
Compd Molecular Formula Found 
Calculated 
Base Peak Molec. Ion 
47a C19H21 NO 135 267 267 
47b C19H21 NO 135 267 267 
47c C19H21 NO 135 267 267 
47d C19H23NO 135 281 281 
47e C22H23NO 135 317 317 
47f C22H23NO 135 317 317 
£Zg C22H23NO 135 317 317 
47h C17H20OS 135 272 272 
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Synthesis of Series IV. Adamantane Moiety Substituted on Aromatic A Ring 52 
l-Adamantyl-4-substituted benzenes 54 A mixture of substituted benzene 47 (10 mL), 
1-bromoadamantane 42 (3.00 g, 13.95 mmol), and a catalytic amount of iron filings was 
heated under vigorous Stirling. The reaction progress was monitored by GC-MS, which 
showed a complete conversion in 90 minutes. The reaction mixture was allowed to cool 
to room temperature and a solid formed. 
Recrystallization from hexane and charcoal afforded pure product of compound 
54. Melting points and percent yield are listed in Table 5. Elemental analysis and GC- 
MS data for these compounds 54 are shown in Table 13 and Table 14 respectively. 
Table 13 
Series IV. Elemental Analysis Data for 
l-Adamantyl-4-substituted Benzenes 54 
Compd Anal. Calcd For 
Calculated Found 
X 
C H C H 
54a C17H22 H 90.51 9.49 90.61 9.56 
54b C17H22O Me 90.20 9.80 90.03 9.82 
54c C16H20 OMe 84.25 9.15 84.10 9.20 
Table 14 
Series IV. GC-MS Data for 
l-Adamantyl-4-substituted Benzenes 54 
Molecular Weight 
Compd Molecular Formula Found 
Calculated 
Base Peak Molec. Ion 
54a C16H20 155 212 212 
54b C17H22 169 226 226 
54c C17H22O 185 242 242 
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5-(l-adamantyl)-2-methoxy acetophenone 50. In a three-necked round bottom 
flask at 0 °C under flow of nitrogen, Aluminum chloride (1.65g, 4.1 mmol) was added to a 
solution of p-(l-adamantyl) anisole 54c (l.OOg, 4.1 mmol) in anhydrous methylene 
chloride (30 ml) followed by drop-wise addition of acetyl chloride (0.6mL, 8.2mmol). 
The reaction mixture was allowed to warm to room temperature and stirring was 
continued overnight. The mixture was poured over crushed ice, extracted with methylene 
chloride (3 x 25 ml), and the combined organic phase was washed with brine (2x15 ml). 
The organic phase was dried over magnesium sulfate and concentrated to afford a 
yellowish solid. The crude product showed two distinct compounds 49 and 50 by GC- 
MS. Compound 49 was the hydrolyzed product of compound 50. The crude product 
was dissolved in DMF (25mL) followed by the addition of iodomethane (3.00 g), and 
potassium carbonate (2.9g). The reaction mixture was allowed to stir over night at room 
temperature. Then it was poured over crushed ice. The pale yellowish solid that formed 
was filtered and washed with ether to give a 73% yield of product 50, and melting point 
108-110 °C. 
Anal. Calcd. for C19H2402: C, 80.24; H, 8.51. Found: C, 79.75; H, 8.46. 
Molecular weight Calculated for C19H24O2: 284. Found: MS m/z 284(M+). 
‘H NMR (400 MHz, CDC13/TMS): ô = 1.74-1.82(m, 6H), 1.92(d, J=2.58, 6H), 2.1 l(br s, 
3H), 263(s, 3H), 3.91(s, 3H), 6.94(d, J=8.69, 1H), 7.48(dd, J 1=2.58, J2=2.58, 1H), and 
7.76(d, J=2.61, 1H); 13C NMR (400 MHz, CDC13/TMS): 5 =29.31, 32.28, 36.1, 37.13, 
43.6,55.9, 111.7, 127.25, 128.10, 130.6, 144.03, 157.3 and 200.63. 
5-(l-Aadamantyl-2-methoxyphenyl)-3-(4-phenylphenyI)prop-2-en-l-one 52 A 
mixture of ketone 49 (l.OOg, 3.52mmol), p-biphenyl benzaldehyde 5! (0.7g, 3.52mmol) 
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and potassium hydroxide (0.4g, 7.04mmol) in ethanol (20mL) was allowed to stir 
overnight at room temperature. The reaction mixture was poured into ice water and a 
yellow solid formed. Filtration followed by recrystalization from ethanol gave (0.7 g, 
45%) of the desire product 52 as yellow needle crystals, m.p. 78.4 - 81.3°. 
Elemental analysis. Calculated for C32H32O2: C, 85.68; H, 7.19. Found: C, 84.81; H, 
7.20. 
'H NMR (400 MHz, CDCI3/TMS): Ô = 1.76-1.84(m, 6H), 1.96(br s, 6H), 2.13(br s, 3H), 
3.93(s, 3H), 6.99(d, 7=8.7, 1H), 7.41(d, 7=7.4, 1H), 7.46-7.53(m,4H), and 7.64-7.74(m, 
8H); 13C NMR (400 MHz, CDCI3/TMS): Ô =29.35, 36.13, 37.13, 43.65, 56.29, 111.88, 
127.44, 127.60, 127.92, 128.2, 129.26, 129.30, 129.90, 134.73, 140.68, 142.66, 143.30, 
144.3, 156.57, and 193.55. 
BIOLOGICAL TESTING 
Cell Culture Methods 
All breast cancer cell lines were purchased from ATCC. MCF-7 and MDA-MB435 
cells were grown in T-75 tissue culture flasks as monolayer cultures in RPMI 1640 
medium (phenol red) supplemented with 2mM glutamine, penicillin (30, 000 units/ml), 
10% calf serum, and fungizone (250 g/ml). Cultures were grown at 37 °C in a humid 5% 
CO2 atmosphere. When cultures reached confluency (usually every 5-7 days), they were 
sub-cultured using a 1:2 splitting ratio. Culture media were changed every three days 
until the cells were confluent. MCF-10 cells were grown in T-75 flasks as monolayer 
cultures in DMEM (phenol red 14.8 g/L), F-12 Ham base supplemented with glutamine 
(200mM), amino acids (50X), fungizone (5ml), insulin (4mg/ml), hydrocortisone (17ml), 
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EGF (2ml), sodium bicarbonate (2.2g), pencillin/streptomycin (10,000 units/ml), chlorea 
toxin (0.49ml), and 10% bovine serum. Cultures were grown at 37 °C in a humid 5% 
CO2 atmosphere. When cultures reach confluence (usually every 5-7 days), they were 
sub-cultured using a 1:2 splitting ratio. Culture media were changed every three days 
until the cells were confluent. 
In Vitro Biological Screening 
Two human breast cancers cell lines (MCF-7 and MDA-MB435) and a normal 
breast epithelial cell line (MCF-10) were obtained from ATCC (American Type Culture 
Collection) to test against the series of compounds and the data were examined for the 
compounds’ relative antiproliferation profiles. All of these cell lines were derived from 
epithelial tissue. These cell lines were selected because they allowed our laboratory to 
investigate the effects of the compounds in: 1) breast neoplasms whose growth is 
stimulated by the presence of estrogen, MCF-7 (ER-positive); 2) Breast neoplasms whose 
growth is not stimulated by estrogen MDA-MB435 (ER-negative); and 3) A non-cancer 
cell line (MCF-10) to compare relative toxcities of the compounds. 
A systematic screening of a novel class of chalcone-like and substituted chalcones 
was performed to examine their relative antiproliferative activity against two human 
breast cancer cell lines. The breast cancer in vitro screening procedure involved the 
plating of MCF-7, MDA-MB435, and MCF-10 cells in a 96 well plate. The cells were 
exposed to the synthesized compounds for two days; and cell growth was determined by 
the alamar blue exclusion dye method, and the concentration that is lethal to 50 percent of 
population of cells LC50 values were analyzed.(see appendix G) 
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Three basic parameters from the results were evaluated: 
A dose response curve for novel chalcone and chalcone-like derivatives over a 
concentration range of ImM to InM was prepared in order to detect the doses where 
possible biological activity might exist. Biological activity was determined by relative 
LD50 values of novel agents. Those compounds that exhibited antiproliferation within the 
established concentration range parameters were examined for their relative biological 
activity and potency versus chalcone compounds with known antibreast cancer activity. 
The chalcone and chalcone-like derivatives were examined against two different types of 
breast cancer cell lines which included estrogen receptor positive (MCF-7), and estrogen 
receptor negative (MDA-MB435)cells. This examination allowed our laboratory to 
determine whether the novel agents exhibited relative selectivity for estrogen stimulated 
breast cancer cell lines. 
The toxicity of the novel compounds for normal breast epithelial cells was 
examined by studying LC50 values of novel agents against a normal breast epithelial cell 
line (MCF-10). 
By examining these three parameters, our laboratory was able to determine 
whether these novel agents possessed any antiproliferative activity against specific breast 
cancer cell lines, MCF-7 (ER+), MDA-MB435 (ER-), and normal breast epithelial 
(MCF-10). By pursuing this examination our laboratory was able to determine that 
whether various ring substitutions enhance the biological activity and/or potency of 
chalcone and chalcone-like compounds. 
Cell Proliferation Studies 
In each experiment, the exponentially growing cells were trypsinized, counted by 
a hemacytometer using the trypan blue exclusion method, and plated in multi-well plates 
at a density of 2xl04 cells per well in 200pl of media. After two days of incubation when 
the sub-cultured cells were in an exponential growth phase, the test compounds were 
added. A solution of the test compounds in dimethyl sulfoxide was diluted in culture 
medium to concentration ranges of InM to ImM and added to cell cultures. Control 
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wells received the same amounts of vehicle alone. After 48 hours of exposure to selected 
novel compounds, the treated cells, MCF-7, MDA-MB435 and MCF-10 cells, were 
evaluated for their relative cell viability by measuring the optical densities (O.D) of the 
treated cells in the 96 well-plates at 590-nm (oxidation) and 570 (reduction) using a 
microwell plate reader. The O.D. was determined by using the alamar blue dye exclusion 
method. Alamar blue dye, an oxidation/reduction indicator, measured the chemical 
environmental changes in media surrounding the cells. Dying cells secreted oxidative 
by-products which reacted with the indicators in the alamar blue turning the media into a 
blue color. Viable cells secreted reduced by-products turning the media a light pink 
color. The microplate reader quantified these color changes into numbers. The 
antiproliferative activity of the test compounds was calculated as a percent of control by 
the following equation: 
viable cells (control) - viable cells (treated) 
Antiproliferative activity =  —      
viable cells (control) 
Growth Factor Protocol 
Cell lines MCF-7 and MDA-MB435 were counted and plated using standard culture 
media in a 96 multi-well plate at a density of 10,000 cells per well, with each well having 
a total volume of 200 pi (cell + media). After a 24-hour recovery period, half of the 
wells on each plate were aspirated using a sterile Pasteur pipette. To each of the 
aspirated wells, 200 pi of stripped media (RPM1 minus all growth factors) were added 
and 1 ng/ml of either EGF or TGF was added to the respective wells. In addition, alamar 
blue was added to the plate at 10% of the total volume. After 24-hour, the plate was 
measured using the BioLinx II program on the spectrophotometer. After the initial 
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reading, the test compounds 47a and 47b were added to the plate in concentrations 
ranging from 10"3 M to 10'9M. 
The cells were given a 48 hour period to metabolize the test compounds in standard 
tissue culture conditions. The plate was then measured again using the 
spectrophotometer microplate reader using the BioLinxIi progam at dual wavelengths of 
550 nm and 630 nm. 
APPENDIX A 
CRYSTALLOGRAPHIC DATA AND ANALYSIS FOR COMPOUND 43g 
Single crystals of 43g suitable enough for X-ray determination analysis were 
grown by slow cooling of ethanol solution. The crystallographic data and the 
experimental parameters are listed in Table 15 and Table 16. The measurements of the 
integrated intensities of the reflection for the triclinic crystal of 43h were carried out on a 
four-circle CAD-4 automatic diffractometer (LmoKa) graphite monochromatore). The 
intensities of 4145 independent non-zero reflections were measured using a crystal of 
dimensions 0.48 x 0.30 x 0.22 mm) with omega scanning. The parameters of the unit cell 
were a=6.5357(4), b= 16.6954(9), c=14.7326 angstroms, alpha=90, beta=93.130(0), 
gamma=90, Z=4, space group P 1 21/nl and d(calc)= 1.226. An ORTEP diagram of 43g 
is given in Figure 2 and bond lengths, and torsion and bond angles are listed in Table 17 
through Table 19 respectively. 
Table 15 
Crystal Data and Experimental Details for 43g 
Crystal habit Z 4 
Crystal size (mm3) 1605.2(3) Ucaic (cm-1 ) 0.569 
Molecular Formula C20H24O2 29 range(°) 15.8-42.6 
Molecular Mass 296.41 Measured refl'ns 25 
Space group P 1 21/n 1 Unique refl’ns 4145 
Unit cell Obs’d refl’ns (1 >3o(\)) 2982 
a (A) 6.5357(4) R 0.040 
b (A) 16.6954(9) Rw 0.053 
c (A) 14.7326(8) GOF 2.729 
a (°) 90 W 4F0V(F0
2) + 0.0004 F0
4) 
3 (°) 93.130(4) (shift/error)™, 0'016 
Y(°) 90 (Final electron density)max 0.16 




Fractional Atomic Coordinates and Equivalent 
Isotropic Thermal Parameters (Â2) for 43g 
Atoms X Y z Beq
J 
01 0.2589(1) 0.36656(5) 0.27717(7) 0.0771(5) 
02 1.2869(1) 0.27657(5) 0.62226(6) 0.0624(4) 
Cl 0.3725(2) 0.42425(6) 0.28327(7) 0.0498(5) 
C2 0.5636(2) 0.42035(6) 0.34239(8) 0.0515(5) 
C3 0.5934(2) 0.36002(6) 0.40046(7) 0.0500(5) 
C4 0.7718(2) 0.34151(6) 0.46050(7) 0.0467(5) 
C5 0.7667(2) 0.27382(6) 0.51561(7) 0.0507(5) 
C6 0.9334(2) 0.25023(6) 0.57114(7) 0.0499(5) 
C7 1.1118(2) 0.29488(6) 0.57228(7) 0.0484(5) 
C8 1.1190(2) 0.36416(7) 0.51945(8) 0.0576(6) 
C9 0.9528(2) 0.38662(7) 0.46427(8) 0.0552(6) 
CIO 0.3244(1) 0.50032(6) 0.22998(7) 0.0410(4) 
Cll 0.1091(2) 0.49523(7) 0.18286(8) 0.0513(5) 
C12 0.0613(2) 0.57188(7) 0.12915(8) 0.0542(6) 
C13 0.0721(2) 0.64338(7) 0.19282(9) 0.0617(6) 
C14 0.2879(2) 0.65012(6) 0.23765(8) 0.0535(5) 
C15 0.3358(2) 0.57437(6) 0.29282(7) 0.0492(5) 
C16 0.4807(2) 0.51116(6) 0.15585(7) 0.0474(5) 
C17 0.4319(2) 0.58771(7) 0.10134(7) 0.0505(5) 
C18 0.2169(2) 0.58175(7) 0.05603(8) 0.0577(6) 
C19 0.4438(2) 0.65979(7) 0.16487(8) 0.0555(6) 
C20 1.2859(2) 0.20690(7) 0.67805(9) 0.0627(7) 
H2 0.662(2) 0.4655(7) 0.3387(8) 0.064(4) 
H3 0.480(2) 0.3210(7) 0.4038(8) 0.064(4) 
H5 0.637(2) 0.2405(7) 0.5137(8) 0.068(4) 
H6 0.921(2) 0.2006(7) 0.6093(8) 0.065(4) 
H8 1.250(2) 0.3969(7) 0.5209(9) 0.076(4) 
H9 0.962(2) 0.4345(7) 0.4288(8) 0.072(4) 
HI la 0.008(2) 0.4874(7) 0.2322(8) 0.066(4) 
HI lb 0.101(2) 0.4485(7) 0.1410(8) 0.071(4) 
H12 -0.075(2) 0.5675(6) 0.1006(8) 0.062(3) 
H13a -0.030(2) 0.6354(7) 0.2427(9) 0.077(4) 
H13b 0.038(2) 0.6957(7) 0.1602(9) 0.081(4) 
H14 0.293(2) 0.6948(7) 0.2785(8) 0.064(4) 
H15a 0.476(2) 0.5792(6) 0.3232(8) 0.068(4) 
H15b 0.234(2) 0.5667(6) 0.3444(8) 0.063(4) 
HI 6a 0.474(2) 0.4613(7) 0.1135(8) 0.065(3) 
H16b 0.623(2) 0.5145(6) 0.1861(7) 0.057(3) 
H17 0.531(2) 0.5936(7) 0.0545(8) 0.064(4) 
HI 8a 0.185(2) 0.6340(7) 0.0201(9) 0.077(4) 
HI 8b 0.211(2) 0.5347(7) 0.0141(8) 0.064(4) 
H19a 0.585(2) 0.6647(7) 0.1959(9) 0.072(4) 
H19b 0.415(2) 0.7118(7) 0.1288(8) 0.068(4) 
H20a 1.253(2) 0.1589(7) 0.6424(9) 0.075(4) 
H20b 1.177(2) 0.2137(8) 0.724(1) 0.101(5) 
H20c 1.420(2) 0.2011(7) 0.7096(9) 0.083(4) 
a Beq = (4/3)*[a2*B11+b
2*B22+c
2*B33+ab(cos y)B12+ac(cos (3)B13 + bc(cos a)B23] 
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Table 17 
Interatomic Distances d (Â) in the Structure of 43g 
Atoms D Atoms D 
01 Cl 1.216(1) C12 C13 1.517(2) 
02 C7 1.361(1) C12 C18 1.530(2) 
02 C20 1.424(1) C12 H12 0.97(1) 
Cl C2 1.485(2) C13 C14 1.528(2) 
Cl CIO 1.517(1) C13 H13a 1.03(1) 
C2 C3 1.329(2) C13 H13b 1.02(1) 
C2 H2 0.99(1) C14 C15 1.527(2) 
C3 C4 1.458(1) C14 C19 1.528(2) 
C3 H3 0.99(1) C14 H14 0.96(1) 
C4 C5 1.393(1) C15 H15a 1.00(1) 
C4 C9 1.401(2) C15 H15b 1.04(1) 
C5 C6 1.384(2) C16 C17 1.534(1) 
C5 H5 1.01(1) C16 H16a 1.04(1) 
C6 C7 1.383(2) C16 H16b 1.01(1) 
C6 H6 1.01(1) C17 Cl 8 1.526(2) 
C7 C8 1.396(2) C17 C19 1.524(2) 
C8 C9 1.373(2) C17 H17 0.98(1) 
C8 H8 1.01(1) C18 HI 8a 1.04(1) 
C9 H9 0.96(1) CIS H18b 1.00(1) 
CIO Cll 1.537(1) C19 HI 9a 1.01(1) 
CIO C15 1.544(1) C19 H19b 1.03(1) 
CIO C16 1.546(1) C20 H20a 0.98(1) 
Cll C12 1.528(2) C20 H20b 1.01(2) 
Cll HI la 1.02(1) C20 H20c 0.97(1) 
Cll HI lb 0.99(1) 
Crystallographic analysis of compound 43 g (Figure 2) is consistent 
predictions of the synthesis. The structure consists of an adamantyl group directly 
attached to a carbonyl subunit followed by a substituted styrene group. The adamantyl 
group is arranged in the least crowded conformation with respect to the carbonyl system. 
Torsion angle cl 1-clCbcl-ol (7.9) show an almost fully eclipsed conformation thus 
allowing for gauche conformation at the most crowded cl5 and cl6 subunits of the 
adamantyl group with respect to the conjugated c2 atom. The large bulk of the adamantyl 
subunit explains the trans conformation of the product as evidenced in proton NMR 
studies. Contrary to our original predictions, the methoxy functionality adopts an 
eclipsed conformation in respect to the aromatic system (generally staggerd 
conformations are at a lower energy than eclipsed conformations). Torsion angles c6-c7- 
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o2-c20 has a magnitude of -0.6. Bond lengths at the adamantane-carbonyl subunit 
interaction cl-clO (1.517 Â) is analog to the usual value for a C(sp3, adamantane)-C(sp2) 
bond length (1.51 À). It is recognized here that this arrangement is most likely an artifact 
of the packing energy within the crystal, and not necessarily representative of the 
structural arrangement in an amorphous or liquid state. Structural data for the aromatic 
subunit shows full aromatic conjugation as depicted by bond lengths and angles c4-c5 
(1.393 Â), c5-c6 (1.384 Â), c9-c4-c5 (117.4), and c6-c7-c8 (119.6) to name a few 
representative examples. All parameters within the adamantyl groups themselves are 
normal. For instance, cl 1 -c 12 bond length has a value of 1.589 À. 
Table 18 
Torrsion Angles in the Structure 43e (deg) 
Atoms Angle Atoms Angle 
C20 02 Cl C6 -0.6(2) C16 CIO Cll C12 -60.0(1) 
C20 02 Cl C8 179.3(1) Cl CIO C15 C14 179.71(9) 
01 Cl Cl C3 -11.8(2) Cll CIO C15 C14 -58.6(1) 
CIO Cl Cl C3 169.3(1) C16 CIO C15 C14 59.1(1) 
01 Cl CIO Cll 7.9(1) Cl CIO C16 C17 179.62(9) 
01 Cl CIO C15 128.9(1) Cll CIO C16 C17 59.3(1) 
01 Cl CIO C16 -111.1(1) C15 CIO C16 C17 -58.9(1) 
C2 Cl CIO Cll -173.19(9) CIO Cll C12 C13 -59.4(1) 
C2 Cl CIO C15 -52.1(1) CIO Cll C12 C18 61.1(1) 
C2 Cl CIO C16 67.8(1) Cll C12 C13 C14 60.7(1) 
Cl C2 C3 C4 176.0(1) C18 C12 C13 C14 -59.4(1) 
C2 C3 C4 C5 -179.8(1) Cll C12 C18 C17 -60.5(1) 
C2 C3 C4 C9 -1.9(2) C13 C12 C18 C17 59.9(1) 
C3 C4 C5 C6 176.9(1) C12 C13 C14 C15 -61.0(1) 
C9 C4 C5 C6 -1.2(2) C12 C13 C14 C19 59.1(1) 
C3 C4 C9 C8 -177.2(1) C13 C14 C15 CIO 60.1(1) 
C5 C4 C9 C8 0.8(2) C19 C14 C15 CIO -60.2(1) 
C4 C5 C6 Cl -0.1(2) C13 C14 C19 C17 -59.3(1) 
C5 • C6 Cl 02 -178.3(1) C15 C14 C19 C17 60.5(1) 
C5 C6 Cl C8 1.8(2) CIO C16 C17 C18 -60.1(1) 
02 C7 C8 C9 177.9(1) CIO C16 C17 C19 60.1(1) 
C6 Cl C8 C9 -2.2(2) C16 C17 C18 C12 60.2(1) 
C7 C8 C9 C4 0.9(2) C19 C17 C18 C12 -60.0(1) 
Cl CIO Cll C12 -179.92(8) C16 C17 C19 C14 -60.3(1) 
C15 CIO Cll C12 57.9(1) C18 C17 C19 C14 59.9(1) 
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Table 19 
Bond Angles co (degrees) in the Structure of 43g 
Atoms 0) 
C7 02 C20 117.73(9) 
01 Cl C2 119.9(1) 
01 Cl CIO 121.1(1) 
C2 Cl CIO 118.96(9) 
Cl C2 C3 120.0(1) 
C! C2 H2 117.4(7) 
C3 C2 H2 122.5(7) 
C2 C3 C4 129.4(1) 
C2 C3 H3 116.6(7) 
C4 C3 H3 113.9(7) 
C3 C4 C5 118.8(1) 
C3 C4 C9 123.8(1) 
C5 C4 C9 117.4(1) 
C4 C5 C6 122.1(1) 
C4 C5 H5 118.5(7) 
C6 C5 H5 119.4(7) 
C5 C6 Cl 119.3(1) 
C5 C6 H6 118.7(7) 
C7 C6 H6 121.9(7) 
02 Cl C6 124.7(1) 
02 Cl C8 115.8(1) 
C6 Cl C8 119.6(1) 
Cl C8 C9 120.5(1) 
Cl C8 H8 119.3(7) 
C9 C8 H8 120.3(7) 
C4 C9 C8 121.0(1) 
C4 C9 H9 120.5(7) 
C8 C9 H9 118.5(7) 
Cl CIO Cll 110.25(8) 
Cl CIO CIS 110.99(8) 
Cl CIO C16 109.71(8) 
Cll CIO C15 109.15(8) 
Cll CIO C16 108.14(8) 
C15 CIO C16 108.53(8) 
CIO Cll C12 110.11(9) 
CIO Cll HI la 107.3(7) 
CIO Cll HI lb 110.0(7) 
C12 Cll HI la 110.9(7) 
C12 Cll HI lb 109.5(7) 
HI la Cll HI lb 109.(1) 
Cll C12 C13 109.7(1) 
Cll C12 C18 109.25(9) 
Cll C12 H12 108.6(7) 
C13 C12 C18 109.9(1) 
C13 C12 H12 109.8(7) 
C18 C12 H12 109.6(7) 
C12 C13 C14 109.64(9) 
Atoms CO 
C12 C13 H13a 109.3(7) 
C12 C13 H13b 112.5(7) 
C14 C13 HI 3a 108.6(8) 
C14 C13 H13b 108.4(7) 
H13a C13 H13b 108(1) 
C13 C14 C15 109.06(9) 
C13 C14 C19 109.9(1) 
C13 C14 H14 109.4(7) 
C15 C14 C19 109.64(9) 
C15 C14 H14 108.1(7) 
C19 C14 H14 110.8(7) 
CIO C15 C14 110.02(8) 
CIO C15 H15a 110.2(7) 
CIO C15 H15b 109.1(6) 
C14 C15 H15a 109.1(6) 
C14 C15 H15b 111.7(6) 
H15a C15 H15b 1061(1) 
CIO C16 C17 109.93(8) 
CIO C16 HI 6a 108.9(7) 
CIO C16 HI 6b 108.9(7) 
C17 C16 H16a 110.7(6) 
C17 C16 H16b 110.1(6) 
H16a C16 H16b 108.3(9) 
C16 C17 C18 109.57(9) 
C16 C17 C19 109.53(9) 
C16 C17 H17 109.1(7) 
C18 C17 C19 109.59(9) 
C18 C17 H17 109. H7) 
C19 C17 H17 110.0(7) 
C12 C18 C17 109.31(9) 
C12 C18 HI 8a 109.1(8) 
C12 C18 H18b 110.2(7) 
C17 C18 HI 8a 108.9(7) 
C17 C18 H18b 109.0(7) 
H18a C18 HI 8b 110.(1) 
C14 C19 C17 109.51(9) 
C14 C19 H19a 108.6(7) 
C14 C19 H19b 109.9(7) 
C17 C19 H19a 110.9(7) 
C17 C19 H19b 110.3(7) 
H19a C19 H19b 1071(1) 
02 C20 H20a 111.6(7) 
02 C20 H20b 108.5(8) 
02 C20 H20c 108.9(7) 
H20a C20 H20b 107(1) 
H20a C20 H20c 109(1) 
H20b C20 H20c 109(1) 
APPENDIX B 
CRYSTALLOGRAPHIC DATA AND ANALYSIS FOR COMPOUND 43h 
Single crystals of 43h suitable enough for X-ray determination analysis were 
grown by slow cooling of hexane solution. The crystallographic data and the 
experimental parameters are listed in Table 20 and Table 21. The measurements of the 
integrated intensities of the reflection for the triclinic crystal of 43h were carried out on a 
four circle CAD-4 automatic diffractometer (LmoKa) graphite monochromatore). The 
intensities of 3512 independent non-zero reflections were measured using a crystal of 
dimensions 0.35 x 0.22 x 0.22 mm) with omega scanning. The parameters of the unit cel! 
were a=9.754(6), b=6.537(2), c=23.717(9), angstroms, alpha=90.73(4), Z=4, space group 
-P 2yn, and d(calc)= 1.249. An ORTEP diagram of 43h is given in Figure 3. Bond 
lengths, torsion and bond angles are listed in Table 22 through Table 24, respectively. 
Table 20 
Crystal Data and Experimental Details for 43h 
Crystal habit Block Z 4 
Crystal size (mm3) Dcaic (g-crrf3) 1.249 
Molecular Formula C19H21OF Fcaic (cm ) 0.637 
Molecular Mass 284.38 20 range(°) 19.1—37.5 
Space group P 1 21/n 1' Measured refl’ns 25 
Unit cell: Unique refl’ns 6783 
a (À) 9.754(6) Obs'd refl'ns (1 >3a(l)) 2072 
b (A) 6.537(2) R 0.053 
c (A) 23.717(9) Rw 0.054 
a (°) 90 GOF 1.653 
m 90.73(4) W 4F02/[a2(F02) + 0.0004 F04] 
7 (°) „ 90 (shift/erroOma* 0.014 




Fractional Atomic Coordinates and Equivalent 
Isotropic Thermal Parameters (Â2) for 43h 
Atom X Y z Bea3 
F 0.1229(1) 0.7696(3) 0.02040(7) 0.117(1) 
0 0.7233(2) -0.0983(3) 0.10039(8) 0.102(1) 
C1 0.7466(2) 0.0742(3) 0.1178(1) 0.068(1) 
C2 0.6477(2) 0.2417(4) 0.1072(1) 0.068(1) 
C3 0.5368(2) 0.2157(4) 0.07568(9) 0.068(1) 
C4 0.4301(2) 0.3643(3) 0.06191(9) 0.062(1) 
C5 0.3251(2) 0.3102(4) 0.0251(1) 0.073(1) 
C6 0.2212(2) 0.4433(4) 0.0111(1) 0.079(2) 
C7 0.2241(2) 0.6346(4) 0.0343(1) 0.079(2) 
C8 0.3240(2) 0.6971(4) 0.0704(1) 0.080(2) 
C9 0.4279(2) 0.5626(4) 0.08399(9) 0.072(1) 
C10 0.8733(2) 0.1192(3) 0.15330(9) 0.053(1) 
C11 0.9677(2) -0.0676(3) 0.15586(9) 0.066(1) 
C12 1.0925(2) -0.0245(3) 0.1934(1) 0.062(1) 
C13 1.1714(2) 0.1573(4) 0.1696(1) 0.073(2) 
C14 1.0782(2) 0.3443(3) 0.1684(1) 0.066(1) 
C15 0.9535(2) 0.3021(3) 0.13042(9) 0.065(1) 
C16 0.8286(2) 0.1693(3) 0.21318(9) 0.060(1) 
C17 0.9530(2) 0.2112(3) 0.25119(9) 0.062(1) 
C18 1.0462(2) 0.0249(4) 0.2528(1) 0.068(1) 
C19 1.0314(2) 0.3933(3) 0.2276(1) 0.068(1) 
H2 0.6646 0.3720 0.1235 0.0890 
H3 0.5249 0.0832 0.0599 0.0890 
H5 0.3248 0.1771 0.0090 0.0961 
H6 0.1494 0.4035 -0.0140 0.1056 
H8 0.3225 0.8310 0.0360 0.1042 
H9 0.4994 0.6054 0.1089 0.0950 
H11a 0.9974 -0.0995 0.1189 0.0880 
H11b 0.9187 -0.1805 0.1707 0.0880 
H12 1.1501 -0.1417 0.1944 0.0830 
H13a 1.2002 0.1267 0.1324 0.0971 
H13b 1.2494 0.1844 0.1928 0.0971 
H14 1.1275 0.4579 0.1540 0.0877 
H15a 0.8959 0.4193 0.1296 0.0840 
H15b 0.9833 0.2723 0.0933 0.0840 
H16a 0.7788 0.0568 0.2279 0.0786 
H16b 0.7715 0.2870 0.2123 0.0786 
H17 0.9233 0.2402 0.2883 0.0809 
H18a 1.1240 0.0529 0.2761 0.0891 
Ht 8b 0.9976 -0.0885 0.2677 0.0891 
H19a 0.9733 0.5099 0.2266 0.0925 
H19b 1.1090 0.4208 0.2510 0.0925 
aBeq = (4/3)*[a2’B1l+b
2*B22+c
2*B33+ab(cos y)B12+ac(cos P)B13 + bc(cos a)B23] 
Crystallographic analysis of compound 43h (Figure 3) is similarly consistent with 
predictions of the synthesis. The structure consists of an adamantyl group directly 
104 
attached to a carbonyl subunit followed by a p-fluorostyrene group. The large bulk of the 
adamantyl group is accounted as follows. The adamantyl group is arranged in the least 
crowded conformation with respect to the carbonyl system. The confrmation izx almost 
fully eclipsed based on torsion angle cll-clO-cl-o (7.4), thus allowing for gauche 
conformation at the most crowded c 15 and cl6 subunits of the adamantyl group with 
respect to the conjugated c2 atom. Bond lengths at the adamantane-carbonyl subunit 
interaction cl-clO (1.516 A) is analog to the usual value for a C(sp , adamantanej-Cfsp") 
bond length (1.51 A). Structural data for the aromatic subunit shows full aromatic 
conjugation as depicted by bond lengths and angles c4-c5 (1.384Â), c5-c6 (1.372 Â), c9- 
c4-c5 (117.2), and c6-c7-c8 (122.9), et cetera. All parameters within the adamantyl 
groups themselves are normal. For instance, cl 1 -c 12 bond length has a value of 1.524 A. 
Table 22 
Interatomic Distances d (Â) in the Structure of 43h 
Atoms D Atoms D 
F Cl 1.362(3) Cll HI lb 0.95 
0 Cl 1.222(3) C12 C13 1.528(3) 
Cl C2 1.478(3) C12 C18 1.521(3) 
Cl CIO 1.516(3) C12 H12 0.95 
C2 C3 1.317(3) C13 C14 1.524(3) 
C2 H2 0.95 C13 HI 3a 0.95 
C3 C4 1.457(3) C13 H13b 0.95 
C3 H3 0.95 C14 C15 1.529(3) 
C4 C5 1.384(3) C14 C19 1.516(3) 
C4 C9 1.399(3) C14 H14 0.95 
C5 C6 1.372(3) C15 H15a 0.95 
C5 H5 0.95 C15 H15b 0.95 
C6 Cl 1.367(4) C16 C17 1.527(3) 
C6 H6 0.95 C16 HI 6a 0.95 
Cl C8 1.351(3) C16 HI 6b 0.95 
C8 C9 1.377(3) C17 C18 1.520(3) 
C8 H8 0.95 C17 C19 1.525(3) 
C9 H9 0.95 C17 H17 0.95 
CIO Cll 1.530(3) C18 HI 8a 0.95 
CIO C15 1.532(3) C18 H18b 0.95 
CIO C16 1.527(3) C19 HI 9a 0.95 
Cll C12 1.524(3) C19 H19b 0.95 
Cll HI la 0.95 
Table 23 
Bond Angles œ (degrees) in the Structure of 43h 
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Atoms a) 
0 C1 C2 120.5(2) 
0 C1 C10 120.9(2) 
C2 C1 C10 118.5(2) 
C1 C2 C3 122.0(2) 
C1 C2 H2 119.0 
C3 C2 H2 119.0 
C2 C3 C4 128.3(2) 
C2 C3 H3 115.8 
C4 C3 H3 115.8 
C3 C4 C5 119.5(2) 
C3 C4 C9 123.3(2) 
C5 C4 C9 117.2(2) 
C4 C5 C6 121.9(2) 
C4 C5 H5 119.0 
C6 C5 H5 119.0 
C5 C6 07 118.2(2) 
C5 C6 H6 120.9 
C7 C6 H6 120.9 
F 07 C6 119.0(2) 
F 07 C8 118.1(2) 
C6 07 C8 122.9(2) 
C7 C8 C9 118.5(2) 
C7 C8 H8 120.7 
C9 C8 H8 120.7 
C4 C9 C8 121.3(2) 
C4 C9 H9 119.4 
C8 C9 H9 119.4 
C1 C10 C11 110.7(2) 
C1 C10 C15 111.8(2) 
C1 C10 C16 108.5(2) 
C11 C10 C15 109.1(2) 
C11 C10 C16 108.3(2) 
C15 C10 C16 108.4(2) 
C10 C11 C12 110.5(2) 
C10 C11 H11a 109.2 
C10 C11 H11b 109.2 
C12 C11 H11a 109.2 
C12 C11 H11 b 109.2 
H11a C11 H11 b 109.5 
C11 C12 C13 109.3(2) 
C11 C12 C18 109.7(2) 
C11 C12 H12 109.5 
C13 C12 C18 109.5(2) 
C13 C12 H12 109.6 
Atoms ct) 
C18 C12 H12 109.3 
C12 C13 C14 109.1(2) 
C12 C13 H13a 109.6 
C12 C13 H13b 109.6 
C14 C13 H13a 109.6 
C14 C13 H13b 109.6 
H13a C13 H13b 109.5 
C13 C14 C15 109.6(2) 
C13 C14 C19 109.8(2) 
C13 C14 H14 109.2 
C15 C14 C19 109.7(2) 
C15 C14 H14 109.3 
C19 C14 H14 109.2 
C10 C15 C14 109.8(2) 
C10 C15 H15a 109.4 
C10 C15 H15b 109.4 
C14 C15 H15a 109.4 
C14 C15 H15b 109.4 
H15a C15 H15b 109.5 
C10 C16 C17 110.7(2) 
C10 C16 H16a 109.2 
C10 C16 H16b 109.2 
C-17 C16 H16a 109.2 
C17 C16 H16b 109.2 
H16a C16 H16b 109.5 
C16 C17 C18 110.0(2) 
C16 C17 C19 108.8(2) 
C16 C17 H17 109.6 
C18 C17 C19 109.4(2) 
C18 C17 H17 109.0 
C19 C17 H17 110.2 
C12 C18 C17 109.3(2) 
C12 C18 H18a 109.5 
C12 C18 H18b 109.5 
C17 C18 H18a 109.5 
C17 C18 H18b 109.5 
H18a C18 H18b 109.5 
C14 C19 C17 109.5(2) 
C14 C19 H19a 109.5 
C14 C19 H19b 109.5 
C17 C19 H19a 109.5 
C17 C19 H19b 109.5 
H19a C19 H19b 109.5 
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Table 24 
Torrsion Angles in the Structure 43h (deg) 
Atoms Angle Atoms Angle 
0 C1 C2 C3 -4.7(4) C1 C10 C15 C14 178.6(2) 
CIO C1 C2 C3 178.4(2) C11 C10 C15 C14 -58.6(2) 
0 C1 C10 C11 7.4(3) C16 C10 C15 C14 59.1(2) 
0 C1 C10 C15 129.2(2) C1 C10 C16 C17 178.7(2) 
0 C1 C10 C16 -111.3(2) C11 C10 C16 C17 58.5(2) 
C2 C1 C10 C11 -175.8(2) C15 C10 C16 C17 -59.7(2) 
C2 C1 C10 C15 -53.9(3) C10 C11 C12 C13 -59.7(2) 
C2 C1 C10 C16 65.5(2) C10 C11 C12 C18 60.3(2) 
C1 C2 C3 C4 179.4(2) C11 C12 C13 C14 60.2(2) 
C2 C3 C4 C5 176.1(2) C18 C12 C13 C14 -59.9(2) 
C2 C3 C4 C9 -3.6(4) C11 C12 C18 C17 -59.5(2) 
C3 C4 C5 C6 179.3(2) C13 C12 C18 C17 60.4(2) 
C9 C4 C5 C6 -1.0(3) C12 C13 C14 C15 -60.8(2) 
C3 C4 C9 C8 -179.1(2) C12 C13 C14 C19 59.8(2) 
C5 C4 C9 C8 1.1(3) C13 C14 C15 C10 60.3(2) 
C4 C5 C6 C7 0.6(3) C19 C14 C15 C10 -60.3(2) 
C5 C6 C7 F 179.1(2) C13 C14 C19 C17 -60.0(2) 
C5 C6 C7 C8 -0.3(4) C15 C14 C19 C17 60.6(2) 
F C7 C8 C9 -179.0(2) C10 C16 C17 C18 -59.5(2) 
C6 C7 C8 C9 0.4(4) C10 C16 C17 C19 50.3(2) 
C7 C8 C9 C4 -0.9(3) C16 C17 C18 C12 59.1(2) 
C1 C10 C11 C12 -177.9(2) C19 C17 C18 C12 -60.4(2) 
C15 C10 C11 C12 58.7(2) C16 C17 C19 C14 -60.0(2) 
C16 C10 C11 C12 -59.1(2) C18 C17 C19 C14 60.1(2) 
APPENDIX C 
CRYSTALLOGRAPHIC DATA AND ANALYSIS FOR COMPOUND 54c 
Single crystals of 54C suitable enough for X-ray determination analysis were 
grown by slow cooling of hexane solution. The crystallogrphic data and the experimental 
parameters are listed in Tables 25 and 26. The structure was solved by direct methods at 
the crystallographic facility at LSU. The measurements of the integrated intensities of 
the reflection for the triclinic crystal of 54C were carried out on a four circle CAD-4 
automatic diffractometer (LrnoKa) graphite monochromatore). The intensities of 6505 
independent non-zero reflections were measured using a crystal of dimensions 6.4 x 9.3 x 
22.9 mm) with omega-scanning. The parameters of the unit cell were a=6.380(1), 
b=9.273(3), c=22.889(4), angstroms, alpha=83.51(2), beta=88.14(2), gamma=75.99(2), 
Z=4, space group P-1, and d(calc)= 1.233 An ORTEP diagram of 54C is given in Figure 7 
and bond lengths and bond torsion angles are listed in Tables 27 and 29, respectively. 
There are two independent molecules in the unit cell. The structure consists of an 
adamantyl group directly attached to a methoxybenzene fragment, as expected from the 
synthesis. The large bulk of the adamantyl group is accounted as follows. The adamantyl 
group is arranged in the least crowded conformation respect to the aromatic system. 
Torsion angles cl2a-clla-cla-c2a (1.3) and c6b-cl lb-clb-c6b (-3.5) show eclipsed 
conformation thus allowing for gauche conformation at the most crowded subunits of the 
adamantyl group with respect to the aromatic system. Interestingly enough, the methoxy 
functionality adopts an eclipsed conformation in respect to the aromatic system. Torsion 
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angles cl7a-ola-cl4a-cl5a and cl7b-olb-cl4b-cl5b are 5.3 and 0.1 respectively. This 
fact is most likely the result of packing energy within the crystal. Bond lengths at the 
adamantane-aromatic subunit junction cla-cl la (1.524) and clb-cl lb (1.523) are analogs 
to the usual value for a C(sp3, adamantane)-C(sp2-aromatic) bond (1.51). Structural data 
for the aromatic subunit shows full aromatic conjugation as depicted by bond lengths and 
angles cl3a-cl4a (1.391), cl4a-cl5a (1.394), cl4b-cl5b (1.383), cl5b-cl6b (1.393), 
cl3a-cl4a-c5a (119.3), cl2a-cl la-cl6a (116.3), cl3b-cl4b-c15b (119.5) and cl2b-cllb- 
cl2b (116.3) to name a few representative examples. All parameters within the adamantyl 
groups themselves are normal. For instance, c2a-c3a, c3a-c9a, clb-c6b and c5b-c6b bond 
lengths have values of 1.534, 1.535, 1.540 and 1.536, respectively. 
Table 25 
Crystal Data and Experimental Details for Compound 54c 
Crystal habit 






















































Fractional Atomic Coordinates and 
Equivalentlsotropic Thermal Parameters (A2) for 54C 
Atoms X Y z Beq
a 
01A 0.8774(2) 0.1699(1) 0.70161(4) 0.0257(5) 
CIA 0.7225(2) 0.2620(1) 0.45388(6) 0.0148(6) 
C2A 0.5184(2) 0.2133(1) 0.43776(6) 0.0180(6) 
C3A 0.4833(2) 0.2358(2) 0.37103(6) 0.0191(6) 
C4A 0.6795(2) 0.1434(2) 0.34057(6) 0.0197(6) 
C5A 0.8822(2) 0.1938(2) 0.35461(6) 0.0170(6) 
C6A 0.9169(2) 0.1696(1) 0.42153(6) 0.0160(6) 
C7A 0.6919(2) 0.4289(1) 0.43006(6) 0.0178(6) 
C8A 0.6564(2) 0.4523(1) 0.36335(6) 0.0171(6) 
C9A 0.4533(2) 0.4022(2) 0.34921(6) 0.0188(6) 
C10A 0.8525(2) 0.3600(2) 0.33280(6) 0.0187(6) 
Cl 1A 0.7621(2) 0.2400(1) 0.51994(6) 0.0146(6) 
C12A 0.6293(2) 0.1792(1) 0.56070(6) 0.0170(6) 
C13A 0.6718(2) 0.1576(2) 0.62040(6) 0.0189(6) 
C14A 0.8491(2) 0.1971(1) 0.64194(6) 0.0178(6) 
C15A 0.9831(2) 0.2597(1) 0.60281(6) 0.0189(6) 
C16A 0.9382(2) 0.2794(1) 0.54298(6) 0.0177(6) 
C17A 1.0458(2) 0.2200(2) 0.72621(6) 0.0276(7) 
01B 0.3128(2) 0.3050(1) -0.18194(4) 0.0285(5) 
C1B 0.2454(2) 0.2298(1) 0.06888(6) 0.0165(6) 
C2B 0.0286(2) 0.3301(2) 0.08783(6) 0.0192(6) 
C3B -0.0022(2) 0.3056(2) 0.15467(6) 0.0210(7) 
C4B 0.1816(2) 0.3463(2) 0.18552(6) 0.0243(7) 
C5B 0.3982(2) 0.2451(2) 0.16839(6) 0.0210(6) 
C6B 0.4289(2) 0.2683(2) 0.10145(6) 0.0188(6) 
C7B 0.2460(2) 0.0648(2) 0.08929(6) 0.0197(6) 
C8B 0.2150(2) 0.0412(2) 0.15626(6) 0.0204(7) 
C9B -0.0015(2) 0.1414(2) 0.17344(6) 0.0232(7) 
C10B 0.3983(2) 0.0814(2) 0.18746(6) 0.0223(7) 
C11B 0.2710(2) 0.2523(1) 0.00230(6) 0.0164(6) 
C12B 0.1245(2) 0.2151(2) -0.03455(6) 0.0230(7) 
C13B 0.1414(2) 0.2333(2) -0.09487(6) 0.0248(7) 
C14B 0.3087(2) 0.2913(2) -0.12147(6) 0.0206(7) 
C15B 0.4556(2) 0.3295(2) -0.08665(6) 0.0205(7) 
C16B 0.4357(2) 0.3099(2) -0.02568(6) 0.0191(6) 
C17B 0.4821(3) 0.3629(2) -0.21034(7) 0.0269(8) 
H21A 0.391(2) 0.272(1) 0.4581(6) 0.018(4) 
H22A 0.537(2) 0.107(2) 0.4528(6) 0.021(4) 
H3A 0.354(2) 0.206(2) 0.3618(6) 0.026(4) 
H41A 0.655(2) 0.154(2) 0.2965(6) 0.024(4) 
H42A 0.700(2) 0.034(2) 0.3551(6) 0.024(4) 
H5 A 1.007(2) 0.134(1) 0.3343(6) 0.017(4) 
H61A 0.940(2) 0.063(1) 0.4360(6) 0.017(4) 
H62A 1.050(2) 0.199(1) 0.4317(6) 0.019(4) 
H71A 0.817(2) 0.465(2) 0.4397(6) 0.027(4) 
no 
Table 26 (Continued) 
H72A 0.567(2) 0.490(2) 0.4495(6) 0.024(4) 
H8A 0.637(2) 0.559(1) 0.3503(5) 0.016(4) 
H91A 0.328(2) 0.461(1) 0.3686(5) 0.018(4) 
H92A 0.423(2) 0.416(1) 0.3059(6) 0.017(4) 
H101A 0.832(2) 0.372(1) 0.2889(6) 0.016(4) 
HI 02 A 0.984(2) 0.395(2) 0.3404(6) 0.031(4) 
H12A 0.501(2) 0.154(1) 0.5476(6) 0.020(4) 
H13A 0.576(2) 0.115(2) 0.6483(6) 0.024(4) 
H15 A 1.101(2) 0.285(2) 0.6172(6) 0.025(4) 
H16A 1.035(2) 0.322(1) 0.5169(6) 0.017(4) 
H21B -0.092(2) 0.309(1) 0.0658(6) 0.018(4) 
H22B 0.030(2) 0.436(2) 0.0760(6) 0.026(4) 
H3B -0.140(2) 0.372(2) 0.1645(6) 0.026(4) 
H41B 0.162(2) 0.332(2) 0.2299(6) 0.028(4) 
H42B 0.181(2) 0.457(2) 0.1725(6) 0.031(4) 
H5B 0.519(2) 0.270(2) 0.1886(6) 0.025(4) 
H61B 0.434(2) 0.375(1) 0.0889(6) 0.021(4) 
H62B 0.568(2) 0.203(1) 0.0907(6) 0.022(4) 
H71B 0.388(2) -0.003(2) 0.0774(6) 0.028(4) 
H72B 0.130(2) 0.035(2) 0.0692(6) 0.027(4) 
H8B 0.215(2) -0.064(1) 0.1663(6) 0.019(4) 
H91B -0.121(2) 0.115(2) 0.1525(6) 0.034(4) 
H92B -0.021(2) 0.123(2) 0.2178(6) 0.030(4) 
H101B 0.379(2) 0.065(2) 0.2319(6) 0.025(4) 
H102B 0.542(2) 0.014(2) 0.1770(6) 0.027(4) 
H12B 0.009(2) 0.174(2) -0.0160(6) 0.035(5) 
H13B 0.042(2) 0.208(2) -0.1201(6) 0.034(5) 
H15B 0.575(2) 0.370(2) -0.1040(6) 0.030(4) 
H16B 0.540(2) 0.336(2) -0.0018(6) 0.022(4) 
H171A 1.036(2) 0.192(2) 0.7704(6) 0.026(4) 
HI 72 A 1.021(2) 0.336(2) 0.7171(7) 0.044(5) 
H173A 1.196(2) 0.169(2) 0.7102(6) 0.037(5) 
H171B 0.462(2) 0.356(2) -0.2538(7) 0.040(5) 
H172B 0.634(2) 0.300(2) -0.1968(7) 0.037(5) 
H173B 0.463(2) 0.473(2) -0.2028(6) 0.026(4) 
a Beq = (4/3)*[a
2*B1l+b
2*B22+c
2*B33+ab(cos y)Bi2+ac(cos (3)B13 + bc(cos a)B23] 
Ill 
Table 27 
Interatomic Distances d (Â) in the Structure of 54C 
Atoms D 
01A C14A 1.370(2) 
01A C17A 1.424(2) 
01A C2A 1.546(2) 
C1A C6A 1.546(2) 
C1A C7A 1.549(2) 
C1A C11A 1.524(2) 
C2A C3A 1.534(2) 
C2A H21A 1.00(1) 
C2A H22A 0.99(1) 
C3A C4A 1.532(2) 
C3A C9A 1.535(2) 
C3A H3A 0.96(2) 
C4A C5A 1.532(2) 
C4A H41A 1.02(1) 
C4A H42A 1 01(1) 
C5A C6A 1.538(2) 
C5A C10A 1.534(2) 
C5A H5A 0.99(1) 
C6A H61A 0.98(1) 
C6A H62A 0.99(1) 
07 A 08A 1.534(2) 
C7A H71A 0.98(2) 
C7A H72A 0.99(1) 
C8A C9A 1.534(2) 
C8A C10A 1.532(2) 
C8A H8A 0.98(1) 
C9A H91A 0.98(1) 
C9A H92A 1.00(1) 
C10A H101A 1.01(1) 
C10A H102A 1.00(2) 
C11A C12A 1.403(2) 
C11A C16A 1.398(2) 
C12A C13A 1.385(2) 
C12A H12A 0.97(1) 
C13A C14A 1.391(2) 
C13A H13A 0.98(1) 
014A 015A 1.394(2) 
015A C16A 1.391(2) 
C15A H15A 0.92(2) 
C16A H16A 0.97(1) 
017A H171A 1.02(1) 
017A H172A 1.04(2) 
C17A H173A 1.04(1) 
Atoms D 
01B C14B 1.376(2) 
01B C17B 1.426(2) 
C1B C2B 1.548(2) 
C1B C6B 1.540(2) 
C1B C7B 1.547(2) 
C1B C11B 1.523(2) 
C2B C3B 1.534(2) 
C2B H21B 1.00(1) 
C2B H22B 0.99(1) 
C3B C4B 1.531(2) 
C3B C9B 1.534(2) 
C3B H3B 0.98(1) 
C4B C5B 1.538(2) 
C4B H41B 1.02(1) 
C4B H42B 1.04(1) 
C5B C6B 1.536(2) 
C5B C10B 1.531(2) 
C5B H5B 0.99(2) 
C6B H61B 1.01(1) 
C6B H62B 0.99(1) 
C7B C8B 1.537(2) 
C7B H71B 1.02(1) 
C7B H72B 0.99(2) 
C8B C9B 1.534(2) 
C8B C10B 1.530(2) 
C8B H8B 0.98(1) 
C9B H91B 1.00(2) 
C9B H92B 1.02(1) 
C10B H101B 1.02(1) 
C10B H102B . 1.02(1) 
C11B C12B 1.406(2) 
C11B C16B 1.397(2) 
C12B C13B 1.376(2) 
C12B H12B 0.97(2) 
C13B C14B 1.400(2) 
C13B H13B 0.96(2) 
C14B C15B 1.383(2) 
C15B C16B 1.393(2) 
C15B H15B 0.98(2) 
C16B H16B 0.97(2) 
C17B H171B 1.02(2) 
C17B H172B 1.04(1) 
C17B H173B 1.03(1) 
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Table 28 
Bond Angles a) (degrees) in the Structure of 54C 
Atoms Ü) 
C14A 01A C17A 117.7(1) 
C2A C1A C6A 107.8(1) 
C2A C1A C7A 107.5(1) 
C2A C1A C11A 112.3(1) 
C6A C1A C7A 108.3(1) 
C6A CIA C11A 110.3(1) 
C7A C1A C11A 110.4(1) 
C1A C2A C3A 111.2(1) 
C1A C2A H21A 109.0(9) 
C1A C2A H22A 107.8(8) 
C3A C2A H21A 110.4(7) 
C3A C2A H22A 110.4(8) 
H21A C2A H22A 107(1) 
C2A C3A C4A 109.6(1) 
C2A C3A C9A 109.0(1) 
C2A C3A H3A 110.1(8) 
C4A C3A C9A 109.8(1) 
C4A C3A H3A 110.2(8) 
C9A C3A H3A 108.1(8) 
C3A C4A C5A 109.5(1) 
C3A C4A H41A 110.4(7) 
C3A C4A H42A 109.8(8) 
C5A C4A H41A 111.2(8) 
C5A C4A H42A 109.2(8) 
H41A C4A H42A 106(1) 
C4A C5A C6A 109.0(1) 
C4A C5A C10A 109.4(1) 
C4A C5A H5A 108.4(9) 
C6A C5A C10A 109.7(1) 
C6A C5A H5A 110.5(7) 
C10A C5A H5A 109.8(8) 
C1A C6A C5A 111.0(1) 
C1A C6A H61A 110.0(7) 
C1A C6A H62A 108.8(8) 
C5A C6A H61A 110.6(8) 
C5A C6A H62A 110.6(7) 
H61A C6A H62A 105(1) 
C1A C7A C8A 111.0(1) 
C1A C7A H71A 110.5(8) 
C1A C7A H72A 109.8(8) 
C8A C7A H71A 110.0(8) 
C8A C7A H72A 109 3(8) 
H71A C7A H72A 106(1) 
C7A C8A C9A 109.4(1) 
C7A C8A C10A 109.5(1) 
C7A C8A H8A 108.2(8) 
Atoms O) 
C14B 01B C17B 117.0(1) 
C2B C1B C6B 108.1(1) 
C2B C1B C7B 108.5(1) 
C2B C1B C11B 110.0(1) 
C6B C1B C7B 107.6(1) 
C6B C1B C11B 112.4(1) 
C7B C1B C11B 110.2(1) 
C1B C2B C3B 110.6(1) 
C1B C2B H21B 109.2(7) 
C1B C2B H22B 108.5(8) 
C3B C2B H21B 112.1(7) 
C3B C2B H22B 109.5(8) 
H21B C2B H22B 106(1) 
C2B C3B C4B 109.5(1) 
C2B C3B C9B 109.8(1) 
C2B C3B H3B 107.5(8) 
C4B C3B C9B 109.5(1) 
C4B C3B H3B 109.4(9) 
C9B C3B H3B 111.2(9) 
C3B C4B C5B 109.2(1) 
C3B C4B H41B 110.1(9) 
C3B C4B H42B 109.1(8) 
C5B C4B H41B 109.3(7) 
C5B C4B H42B 109.8(8) 
H41B C4B H42B 109(1) 
C4B C5B C6B 109.2(1) 
C4B C5B C10B 109.5(1) 
C4B C5B H5B 109.9(8) 
C6B C5B C10B 109.7(1) 
C6B C5B H5B 110.0(8) 
C10B C5B H5B 108.5(8) 
C1B C6B C5B 111.2(1) 
C1B C6B H61B 109.7(8) 
C1B C6B H62B 109.0(9) 
C5B C6B H61B 109.8(8) 
C5B C6B H62B 108.9(7) 
H61B C6B H62B 108(1) 
C1B C7B C8B 110.8(1) 
C1B C7B H71B 109.8(9) 
C1B C7B H72B 110.1(8) 
C8B C7B H71B 109.9(8) 
C8B C7B H72B 109.7(8) 
H71B C7B H72B 106(1) 
C7B C8B C9B 109.4(1) 
C7B C8B C10B 109.9(1) 
C7B C8B H8B 106.9(8) 
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C9A C8A C10A 109.5(1) C9B C8B C10B 109.3(1) 
C9A C8A H8A 109.6(8) C9B C8B H8B 110.2(7) 
C10A C8A H8A 110.5(7) C10B C8B H8B 111.1(8) 
C3A C9A C8A 109.3(1) C3B C9B C8B 109.5(1) 
C3A C9A H91A 109.4(8) C3B C9B H91B 108.9(8) 
C3A C9A H92A 108.2(8) C3B C9B H92B 110.6(9) 
C8A C9A H91A 109.9(9) C8B C9B H91B 108.9(8) 
C8A C9A H92A 112.2(8) C8B C9B H92B 108.5(7) 
H91A C9A H92A 108(1) H91B C9B H92B 110(1) 
C5A C10A C8A 109.7(1) C5B C10B C8B 109.2(1) 
C5A C10A H101A 107.6(8) C5B C10B H101 B 110.2(8) 
C5A C10A H102A 111.0(8) C5B C10B H102B 110.0(9) 
C8A 01OA H101A 111.1(7) C8B C10B H101B 110.1(9) 
C8A C10A H102A 110.0(8) C8B C10B H102B 109.7(9) 
H101A C10A H102A 107(1) H101B C10B H102B 107(1) 
C1A C11A C12A 123.1(1) C1B C11B C12B 120.3(1) 
C1A C11A C16A 120.6(1) C1B C11B C16B 123.4(1) 
C12A C11A C16A 116.4(1) C12B C11B C16B 116.3(1) 
C11A C12A C13A 121.8(1) C11B C12B C13B 122.3(1) 
C11A C12A H12A 120.2(8) C11B C12B H12B 117.6(9) 
C13A 012A H12A 117.9(8) C13B C12B H12B 120.0(9) 
C12A C13A C14A 120.5(1) C12B C13B C14B 119.9(1) 
C12A C13A H13A 120.6(9) C12B C13B H13B 122.6(9) 
C14A C13A H13A 118.9(9) C14B C13B H13B 117.6(9) 
01A C14A C13A 115.7(1) 01B C14B C13B 115.6(1) 
01A 014A C15A 124.9(1) 01B C14B C15B 124.9(1) 
C13A C14A C15A 119.3(1) C13B C14B C15B 119.5(1) 
C14A C15A C16A 119.2(1) C14B C15B C16B 119.8(1) 
C14A C15A H15A 119.2(8) C14B C15B H15B 121.4(9) 
C16A C15A H15A 121.6(8) C16B C15B H15B 118.8(9) 
C11A C16A 015A 122.8(1) C11B C16B C15B 122.3(1) 
C11A C16A H16A 119.8(8) C11B C16B H16B 118.7(8) 
C15A C16A H16A 117.4(8) C15B C16B H16B 119.0(8) 
01A C17A H171A 105.0(9) 01B 017B H171B 104.(1) 
01A C17A H172A 110.6(9) 01B C17B H172B 112.1(9) 
01A 017A H173A 112(1) 01B C17B H173B 109.7(8) 
M171A C17A H172A 109(1) H171B C17B H172B 109(1) 
H171A C17A H173A 110(1) H171B C17B H173B 110(1) 
H172A C17A H173A 108(1) H172B C17B H173B 110(1) 
Table 29 
Torrsion Angles in the Structure 54C (deg) 
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Atoms Angle 
C17A 01A C14A C13A -174.8(1) 
C17A 01A C14A C15A 5.3(2) 
C6A C1A C2A C3A -57.9(1) 
C7A C1A C2A C3A 58.7(1) 
C11A C1A C2A C3A -179.6(1) 
C2A C1A C6A C5A 58.5(1) 
C7A 01A C6A C5A -57.5(1) 
C11A C1A C6A C5A -178.5(1) 
C2A C1A C7A C8A -58.3(1) 
C6A C1A C7A C8A 57.9(1) 
C11A C1A C7A C8A 178.8(1) 
C2A C1A C11A C12A 1.3(2) 
C2A C1A C11A C16A -179.3(1) 
C6A C1A C11A C12A -119.0(1) 
C6A C1A C11A C16A 60.4(2) 
C7A CIA Cl 1A C12A 121.3(1) 
C7A C1A C11A C16 A -59.3(2) 
C1A C2A C3A C4A 59.5(1) 
C1A C2A C3A C9A -60.7(1) 
C2A C3A C4A C5A -59.9(1) 
C9A C3A C4A C5A 59.9(1) 
C2A C3A C9A C8A 60.3(1) 
C4A C3A C9A C8A -59.8(1) 
C3A C4A C5A C6A 60.2(1) 
C3A C4A C5A C10A -59.7(1) 
C4A C5A C6A C1A -60.6(1) 
C10A C5A C6A C1A 59.2(1) 
C4A C5A C10A C8A 59.9(1) 
C6A C5A C10A C8A -59.7(1) 
C1A C7A C8A C9A 60.2(1) 
C1A C7A C8A C10A -59.8(1) 
C7A C8A C9A C3A -60.3(1) 
C10A C8A C9A C3A 59.8(1) 
C7A C8A C10A C5A 60.0(1) 
C9A C8A C10A C5A -60.0(1) 
C1A C11A C12A C13A 178.6(1) 
C16A C11A C12A C13A -0.7(2) 
C1A C11A C16A C15A -179.1(1) 
C12A C11A C16A C15A 0.3(2) 
C11A C12A C13A C14A 0.4(2) 
Cl 2 A C13A C14A 01A -179.5(1) 
C12A C13A C14A C15A 0.5(2) 
01A C14A C15A C16A 179.0(1) 
C13A C14A C15A C16A -0.9(2) 
C14A C15A C16A C11A 0.5(2) 
Atoms Angle 
C17B 01B C14B C13B -179.6(1) 
C17B 01B C14B C15B 0.1(2) 
C6B C1B C2B C3B -58.4(1) 
C7B C1B C2B C3B 58.0(1) 
C11B C1B C2B C3B 178.5(1) 
C2B C1B C6B C5B 58.2(1) 
C7B C1B C6B C5B -58.7(1) 
C11B C1B C6B C5B 179.8(1) 
C2B C1B C7B C8B -58.3(1) 
C6B C1B C7B C8B 58.4(1) 
C11B C1B C7B C8B -178.7(1) 
C2B C1B C11B C12B -62.8(2) 
C2B C1B C11B C16B 117.0(1) 
C6B C1B C11B C12B 176.7(1) 
C6B C1B C11B C16B -3.5(2) 
C7B C1B C11B C12B 56.7(2) 
C7B C1B C11B C16B -123.5(1) 
C1B C2B C3B C4B 60.6(1) 
C1B C2B C3B C9B -59.7(1) 
C2B C3B 04 B C5B -60.6(1) 
C9B C3B C4B C5B 59.8(1) 
C2B C3B 09 B C8B 60.1(1) 
C4B C3B C9B C8B -60.1(1) 
C3B C4B C5B C6B 60.0(1) 
C3B C4B C5B C10B -60.2(1) 
C4B C5B C6B C1B -59.8(1) 
C10B C5B C6B C1B 60.2(1) 
C4B C5B C10B C8B 60.6(1) 
C6B C5B C10B C8B -59.3(1) 
C1B C7B C8B C9B 59.9(1) 
C1B C7B C8B C10B -60.1(1) 
C7B C8B C9B C3B -60.0(1) 
C10B C8B C9B C3B 60.4(1) 
C7B C8B C10B C5B 59.4(1) 
C9B C8B C10B C5B -60.6(1) 
C1B C11B C12B C13B -179.9(1) 
C16B C11B C12B C13B 0.3(2) 
C1B C11B C16B C15B -179.9(1) 
C12B C11B C16B C15B -0.1(2) 
C11B C12B C13B C14B -0.3(2) 
C12B C13B C14B 01B 179.8(1) 
C12B C13B C14B C15B 0.1(2) 
01B C14B C15B C16B -179.6(1) 
C13B C14B C15B C16B 0.1(2) 
C14B C15B C16B C11B -0.0(2) 
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APPENDIX C 
NMR DATA FOR SERIES I COMPOUNDS 
Table 30 
Series I. *H and 13C NMR Data for 
Chalcone-Like Compounds 43 Synthesized 
with Aromatic A Ring Replaced by the Adamantane Moiety 
Compd X ‘H NMR (CDC1/TMS) ô, J (Hz) 13C NMR (CDC13/TMS) 8 
43a H 1.78(q, J, = 9.9, J2 = 11.1, 6H), 
1.92(br s, 6H), 2.1 l(br s, 3H), 
7.18(d, J = 15.6, 1H), 7.39 - 
7.41(m, 3H), 7.58 - 7.61(m, 2H), 
7.69(d, J = 15.6, 1H), 
28.40, 37.03, 38.48, 45.94, 
120.77, 128.66, 129.23, 130.51, 
135.53, 143.23, 204.17 
43b CN 1.78(q, i/= 14.1, J2 = 12.4), 6H), 
1.89(br s, 6H), 2.1 l(br s, 3H), 
7.23(d, J = 15.6, 1H), 7.63(d, J = 
15.6, lH),7.67(s,4H) 
28.27, 36.91, 38.31, 46.11, 
113.54, 118.83, 123.93, 128.96, 
132.96, 139.86, 140.74, 203.6 
43c NO2 1.78(q, J, = 13.9, y2 = 19.24, 6H), 
1.92(br s, 6H), 2.13(br s, 3H), 
7.28(d, J = 15.7, 1H), 7.68(d, J = 
15.7, 1H), 7.72(d, J = 8.4, 2H), 
8.26(d, J = 8.4, 2H) 
28.27, 36.91. 38.3, 46.15, 124.5, 
124.6, 129.17, 140.23, 141.73, 
148.78, 203.55 
43d Cl 1.78(q, J, = 11.6, J2 = 12.0), 
1.90(br s, 6H), 2.10(br s, 3H), 
7.14(d, J = 15.6, 1H), 7.36(d, J = 
8.3, 2H), 7.5 l(d, J = 8.5, 2H), 
7.62(d, J = 15.6, 1H) 
28.36, 36.99, 38.43, 45.96, 
121.21, 129.48, 129.81, 134.01, 
136.35, 141.77,203.93 
43e N(CH3)2 1.84 - 1.72(m, 6H), 1.92(s, 6H), 
2.10(br s, 3H), 3.03(s, 6H), 
6.68(d, J = 8.7, 2H), 6.98(d, J = 
15.4, 1H), 7.49(d, J = 8.7, 2H), 
7.67(d,7= 15.4, 1H) 
28.55, 37.13, 38.79, 40.53, 45.66, 
112.22, 115.68, 123.32, 130.44, 
143.99, 152.17, 204.33 
43f CH(CH3)2 1.28(d, J = 7.1, 6H), 1.78(q, J, = 
9.5,J2= 12.1, 6H), 1.92(br s, 6H), 
2.11 (br s, 3H), 2.86 - 3.06(m, 
1H), 7.15(d, J = 15.9, 2H), 
7.26(d, J = 7.7, 2H), 7.53(d, J = 
7.7, 2H), 7.69(d, J = 15.6, 1H) 
24.18, 28.43, 34.5, 37.05, 38.52, 
45.89, 119.87, 127.34, 128.79, 
133.17, 143.28, 151.86,204.28 
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43g OCH, 1.77(q, J, = 9.2, J: = 10.7, 6H), 
1.90(br s, 6H), 2.10(br s, 3H), 
3.84(s, 3H), 6.91 (d, J = 8.6, 2H), 
7.05(d, J = 15.4, 1H), 7.54(d, J = 
8.6, 2H), 7.65(d, J = 15.5, 1H) 
28.44, 37.05, 38.58, 45.8, 55.74, 
114.68, 118.46, 128.23, 130.34, 
142.98. 161.73, 204.19 
43h F (p) 1.78(q, J, = 12.2, J2 = 12.6, 6H), 
1.9(br s, 6H), 2.1(br s, 3H), 7.06 - 
7.12(m, 3H), 7.56 - 7.59(m, 2H), 
7.64(d, J = 15.6, 1H) 
431 Br (o) 1.78(q, J, = 12.9, J: = 13.7, 6H), 
1.91 (br s, 6H), 2.12(br s, 3H), 
7.12(d, J = 15.7, 1H), 7.22(t, J = 
7.7, 1H), 7.33(t, J = 7.5, 1H), 
8.02(d, J = 15.7, 1H) 
28.35, 36.94, 38.39, 45.99, 
123.57, 126.16, 127.95, 128.2, 
131.36, 133.89, 135.66, 141.54, 
203.64 
43j OCFFPh {p) 1.79(q, J, = 9.6, J2 = 10.9, 6H), 
1.92(s, 6H), 2.12(s, 3H), 5.12(s, 
2H), 7.00(d, J = 8.7, IH), 7.07(d, 
J = 15.5, 1H), 7.36-7.46(m, 5H) 
7.56(d, J = 8.7, 2H), 7.67(d, J = 
15.5, 1H) 
28.46, 37.07, 38.6, 45.83, 70.5, 
1 15.61, 118.62, 127.87, 128.5, 
129.06, 130.38, 136.93, 142.94, 
160.91, 204.2 
43k Ph (p) 1.80(q, J, = 8.78, J2 = 10.4, 
6H), 1.95(br s, 6H), 2.13(br s, 
3H), 7.23(d, J = 15.4, 1H), 
7.4(t, J = 7.5, 1 H), 7.48(t, J = 
7.5, 2H) 7.63-7.69(m, 6H) 
7.74(d, J = 15.6, 1H). 
28.43, 37.06, 38.52, 45.97, 
120.64,127.45, 127.89 
128.21, 129.2, 129.3, 134.5, 
140.66, 142.8, 143.3, 204.16 
431 CH2CH3 (p) I. 27(t, J= 7.6, 3H) 1.78(q, J, = 
I , J2 = 12.0, 6H), 1.92(s, 
6H), 2.11 (s, 3H), 2.71 (q, J, = 
7.56, J2 = 7.6, 3H) , 7.15(d, J = 
15.7, 1H), 7.23(d, J = 7.8, 2H), 
7.52(d, J= 8.6, 2H), 7.68(d, J 
= 15.6, 1H) 
15.76, 28.43, 29.22 37.04, 
38.52, 45.88, 119.81, 128.77, 
133.02, 143.32, 147.26, 
204.28 
APPENDIX D 
NMR DATA FOR SERIES II COMPOUNDS 
Table 31 
Series II. *H and 13C NMR 
Data For Chalcone-Like Compounds 
45 Synthesized with Modifications in A and B Regions 
Compd X Y ‘H NMR (CDC1/TMS) 5, J 
(Hz) 
13C NMR (CDCI3/TMS) 5 
45a OCH, H 
1.77(q, J, = 11.03, J2 = 11.6, 
6H), 1.88(br s, 6H), 2.09(br s, 
3H), 3.9(s, 3H), 6.7(d, J = 
14.8, 1H), 6.90 - 7.03(m, 3H), 
7.28 - 7.32(m, 2H), 7.47 - 
7.52(m, 2H) 
28.44, 37.06, 38.53, 45.67, 
55.9, 11 1.51, 121.12, 123.69, 
125.74, 127.81, 128.05, 
130.46, 136.71, 144.28, 
157.9, 204.53 
45b H CHj 
1.78(q, J, = 11.9, J = 13.7, 
6H), 1.9(br s, 6H), 2.1 l(s, 3H), 
6.70(d, J = 15.2, 1H), 6.92(s, 
1H), 7.27 - 7.43(m, 5H), 
7.51 (d. J - 15.2, 1H) 
14.36, 28.45, 37.05, 38.62, 
45.85, 120.02, 128.04, 128.7, 
129.87, 135.02, 137.34, 
139.94, 148.54, 204.51 
45c H Cl 
1.76(s, 6H), 1.88(s, 6H), 
2.10(s, 3H), 7.032(d, J = 14.6, 
1H), 7.38-7.49(m, 4H), 7.77(d, 
J = 9.6, 1H). 
27.88, 36.51, 37.89, 45.58, 
122.95, 124.45, 128.39, 
129.26, 129.63, 130.14, 
135.92, 141.83, 198.88. 
117 
APPENDIX E 
NMR DATA FOR SERIES III COMPOUNDS 
Table 32 
Series III. *H and 13C NMR 
Data for Chalcone-Like Compounds 47 
with Aromatic C Ring Substituted by Heterocycle Ring 
Compd 1H NMR (CDCI3/TMS) S, J (Hz) 
47a 1.77(q, J, = 16.0, J2 = 12.0, 6H), 1.89(br s, 6H), 2.10(br s, 
3H), 6.93-7.00(m, 1H), 7.10(d, J= 8.8, 1H), 7.34-7.46(m, 
3H), 8.35(d, J = 4.6, 1H). 
47b 1,75(q, J, = 11.9, J2 = 12.1,6H), 1,88(br s, 6H), 2.08(br s, 
3H), 7.21 (d, J= 15.7, 1 H), 7.23-7.33(m, 1H) 7.62(d, J = 
15.7, 1 H), 7.86(d, J = 7.9, 1H), 8.58(s, 1 H), 8.78(s, 1 H) 
47c 1.77(q, J, = 16.0, J2= 12.0, 6H), 1.89(br s, 6H), 2.10(br s, 
3H), 7.28(d, J = 16.0, 1H), 7.41 (d, J = 4, 2H), 7.55(d, J = 
16.0, 1 H), 8.65(d, J = 4.0, 2H). 
47d 1.76(s, 6H), 1.93(s, 6H), 2.09(s, 3H), 2.60(s, 3H), 7.12(d, 
J = 7.6, 1H), 7.21 (d, J=7.6, 1H), 7.56(d, J = 7.4, 1H), 
7.63(d, J = 6.1,2H). 
47e 1.77-1.85(m, 6H), 1.98(br s, 6H), 2.14(br s, 3H), 7.55- 
7.65(m, 2H), 7.74(t, J = 8.13, 1H) 7.81-7.83(m, 3H), 8.14- 
8.20(m, 2H). 
47f 1.80(q, J, = 12.25, J2= 12.23, 6H), 1,95(br s, 6H), 2.14(br 
s, 3H), 7.34(d, J= 14.8, 1H), 7.60-7.68(m, 2H), 7.77(t, J = 
8.1, 1H), 8.18(t, J = 8.0, 2H), 8.39(d, J = 15.5, 1H), 
8.95(d, J = 4.5, 1H). 
47g 1.80(q, J1 = 12.51, J2 = 8.40, 6H), 1.96(br s, 6H), 2.14(br 
s, 3H), 7.38(d, J = 8.0, 1H) 7.60(t, J = 8.0, 1H), 7.75- 
7.89(m, 3H), 8.13(d, J = 8.41, 1H), 8.29(s, 1H), 9.15(s, 
1H) 
47h 1.78(q, 12.34, J2= 10.25, 6H), 1.90(br s, 6H), 2.11 (br 
s, 3H), 7.02(d, J= 15.51, 1 H) 7.36(s, 2H), 7.54(s, 1H), 
7.67(d, J= 15.48, 1H). 
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APPENDIX F 
NMR DATA FOR SERIES IV COMPOUNDS 
Table 33 
Series IV. ‘H and 13C NMR 
Data for Synthesized Chalcones with 
Adamantane Moiety Substituted on Aromatic A Ring 
Compd X *H NMR (CDC13/TMS) S, J (Hz) 13C NMR (CDC13/TMS) Ô 
54a H 
1.77 (s,6H), 1.92 (s, 6 H), 2.10 (s, 3 
H. 1.2-1 A (m, 5 H) 
28.96, 36.15, 36.81, 43.15, 124.79, 
125.45, 128.04, 151.25 
54b Me 
1 74 (s, 6 H), 1.87 (d, J = 2.9, 6 H), 
2.06 (br s, 3 H), 2.30 (s, 3 H), 7.11 
(d, J = 8.0, 2 H), 7.24 (d, J = 8.0, 2 
H) 
20.93, 29.13, 33.05, 36.96, 43.40, 
124.79, 128.89, 134.96, 148.55 
54c OMe 
1.76 (s, 6 H), 1.88 (s, 6 H), 2.08 (s, 3 
H), 6.85 (d, 7 = 6.8, 2 H), 7.27 (d ,J = 
6.8, 2 H) 
28.88, 36.70, 36.85, 43.28. 54.83, 
113.30, 125.69, 126.70, 143.63 
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APPENDIX G 
TISSUE CULTURE PROCEDURES 
PREPARATION OF RPMI1640 WITH 10% FBS MEDIA: 
1. Use 500ml bottle of RPMI 1640 with phenol red, glutamine, and sodium bicarbonate 
or 20 mM hepes. 
2. Remove 56 ml RPMI from bottle using a pipette; discard. 
3. Using a syringe or bottle top filter, add 50 ml FBS (Fetal Bovine Serum), 2.5 ml 
insulin, and 3.0 ml pen/strept. 
4. Store at 4 °C and use only in sterile conditions. 
FEEDING OF CELLS/CHANGING MEDIA OF CELLS: 
1. Warm media at 37 °C for 12-15 minutes before using in any procedure. 
2. Use 75% EtOH to wash/clean bottle before placing in hood. 
3. Have the burner and vacuum lines connected and running. 
4. Flame the necks of all bottles and flasks before opening. 
5. Open the bottle/flask, careful to leave the cap turned up. 
6. Using a sterile Pasteur pipette connected to the trap (vacuum), carefully insert into the 
flask, careful to touch only the liquid; throw away the pipette after use. 
7. Using a 10 ml pipette, carefully add 10-12 ml media 
8. Replace lid and return to incubator. 
SPLITTING/TRYPSINIZING OF CELLS: 
1. Wash cells in 5 ml of lx PBS (phosphate buffer solution) by using the lOx stock 
solution and adding 100 ml lOx PBS to 900 ml sterile water; store at 4 °C. Must be 
warmed before using. 
2. Use a Pasteur pipette to remove the PBS from the flask containing the cells. 
3. Add 5-ml trypsin to the flask; rotate flask to insure that the floor of the flask is 
completely covered, return to the incubator for five minutes. 
4. Add 5 ml of media to the flask; wash down the floor of the flask and collect cells, 
placing them in a 15-ml sterile tube. 
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5. Spin cells at 1000G for five minutes; use care not to disturb the pallet. 
6. Aspirate supernatant by using a Pasteur pipette. 
7. Resuspend cells in 10 ml of fresh media; place 5 ml of the cells in one flask and 5 ml 
cells into another flask. 
8. Add 10 ml media to both flask; return to the incubator. 
COUNTING OF CELLS: 
1) Collect 20 p.1 of ceils using a pipeteman and sterile tips; add to an eppendorf tube. 
2) Add 20 |xl trypan blue; mix well (go to microscope; this is done outside of the sterile 
hood). 
3) With the glass slip in place, using the pipetman, carefully add 20 jxl of the mixture 
under the slip of the hemocytometer. 
4) Using the microscope locates a 16-box grid and counts the cells in that region only. 
5) Repeat this procedure on the other side of the hemocytometer. 
6) Take the average of the number of cells viewed in both grids, then apply the 
following formula to determine the amount of cells to add to each well of the 96 well 
plate: 
Assume the average is 40 cells (30, 50); 
a) Double the average (40 x 2 = 80) 
b) Multiply this number by 10,000 (10,000 x 80) 
c) This gives you the number of cells per ml 
d) Take the figure and divide by 1000 (800,000 divided by 1000) 
e) This gives you cells per microliter (800 cells per microliter) 
f) 10,000 (number of cells needed per well, may vary) divide by 800 gives the number 
of microliters of cells to add per well. In this case, it is 12.5 (il. 
ADDING CELLS TO THE 96 WELL PLATE: 
1) The total volume of cells + media in the plate is always 200 p.1, therefore counting 
with the example above, the difference is 187.5 |xl of media per well. 
2) Always add the media first; using the multipippeter add 187.5 p.1 to each well; place 
the media in a well-dispenser for accuracy. 
3) Using the same technique, add the cells to the wells, taking care to pipette effectively. 
4) Cover and place in incubator allowing time for the cells to attach. Time may vary 
according to the various cell lines. 
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ADDITION OF DRUG TO THE PLATE: 
ADDITION OF ALAMAR BLUE: 
1. After the drug has been metabolized for 24 hours, the dye is added at a 10% total 
volume. 
2. Assuming 187.5 )il media + 12.5 pi cells + 100 pi drug have been added to each well, 
the total volume is 300 pi. 
3. Therefore, add 30 pi alamar blue to each well with an incubation time of 24 hours. 
4. This is a light-sensetive reaction and should be done with the hood light off. 
ANALYZING OF DATA: 
1. The spectrophotmeter requires that the BioLinks II program be used. 
2. Two wavelengths are used: 550 nm and 630 nm. 
3. After plates are read, they may be disposed of, assuming no additional reading will be 
taken 
4. The program provides the optical density (O.D.) at each wavelength. 
5. The percent change in color was used as an indication of cell viability. 
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